Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,19451403,half-life,Lenalidomide exhibited a linear pharmacokinetics over a wide range of doses with the mean half-life of 3.9 hours.,Phase I study of oral lenalidomide in patients with refractory metastatic cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19451403/),h,3.9,1887,DB01041,Thalidomide
,19451403,CL/F,"The renal function affected lenalidomide clearance, resulting in 50% reduction in patients with mild renal impairment compared with patients with normal function (CL/F = 243 mL/min).",Phase I study of oral lenalidomide in patients with refractory metastatic cancer. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19451403/),[ml] / [min],243,1888,DB01041,Thalidomide
,25594893,flow rate,"Chromatographic separation of analytes was performed on YMC pack ODS AM (150 mm × 4.6 mm, 5 μm) column under gradient conditions with acetonitrile:0.1% formic acid buffer as the mobile phases at a flow rate of 1 ml/min.","Simultaneous quantification of lenalidomide, ibrutinib and its active metabolite PCI-45227 in rat plasma by LC-MS/MS: application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25594893/),[ml] / [min],1,10969,DB01041,Thalidomide
,25594893,extraction recovery,"Mean extraction recovery for ibrutinib, PCI-45227, lenalidomide and IS of 75.2%, 84.5%, 97.3% and 92.3% were consistent across low, medium, and high QC levels.","Simultaneous quantification of lenalidomide, ibrutinib and its active metabolite PCI-45227 in rat plasma by LC-MS/MS: application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25594893/),%,75.2,10970,DB01041,Thalidomide
,25594893,extraction recovery,"Mean extraction recovery for ibrutinib, PCI-45227, lenalidomide and IS of 75.2%, 84.5%, 97.3% and 92.3% were consistent across low, medium, and high QC levels.","Simultaneous quantification of lenalidomide, ibrutinib and its active metabolite PCI-45227 in rat plasma by LC-MS/MS: application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25594893/),%,84.5,10971,DB01041,Thalidomide
,25594893,extraction recovery,"Mean extraction recovery for ibrutinib, PCI-45227, lenalidomide and IS of 75.2%, 84.5%, 97.3% and 92.3% were consistent across low, medium, and high QC levels.","Simultaneous quantification of lenalidomide, ibrutinib and its active metabolite PCI-45227 in rat plasma by LC-MS/MS: application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25594893/),%,97.3,10972,DB01041,Thalidomide
,25594893,extraction recovery,"Mean extraction recovery for ibrutinib, PCI-45227, lenalidomide and IS of 75.2%, 84.5%, 97.3% and 92.3% were consistent across low, medium, and high QC levels.","Simultaneous quantification of lenalidomide, ibrutinib and its active metabolite PCI-45227 in rat plasma by LC-MS/MS: application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25594893/),%,92.3,10973,DB01041,Thalidomide
,16680463,area under the time-concentration curve (AUC),"Indeed, area under the time-concentration curve (AUC) of SN-38 was significantly lower at the first cycle than the second cycle (0.99+/-0.45 hxmicrog/ml vs 1.34+/-0.65, respectively, P=0.027) whereas AUC of irinotecan and SN-38-glucuronide were higher at first cycle than second cycle (34.53+/-11.38 hxmicrog/ml vs. 28.42+/-12.23 hxmicrog/ml, P=0.064 and 2.39+/-1.21 h(microg/ml vs. 1.86+/-1.11 hxmicrog/ml, P=0.018, respectively).",Irinotecan in combination with thalidomide in patients with advanced solid tumors: a clinical study with pharmacodynamic and pharmacokinetic evaluation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16680463/),[h·μg] / [ml],0.99,15965,DB01041,Thalidomide
,16680463,area under the time-concentration curve (AUC),"Indeed, area under the time-concentration curve (AUC) of SN-38 was significantly lower at the first cycle than the second cycle (0.99+/-0.45 hxmicrog/ml vs 1.34+/-0.65, respectively, P=0.027) whereas AUC of irinotecan and SN-38-glucuronide were higher at first cycle than second cycle (34.53+/-11.38 hxmicrog/ml vs. 28.42+/-12.23 hxmicrog/ml, P=0.064 and 2.39+/-1.21 h(microg/ml vs. 1.86+/-1.11 hxmicrog/ml, P=0.018, respectively).",Irinotecan in combination with thalidomide in patients with advanced solid tumors: a clinical study with pharmacodynamic and pharmacokinetic evaluation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16680463/),,1.34,15966,DB01041,Thalidomide
,16680463,AUC,"Indeed, area under the time-concentration curve (AUC) of SN-38 was significantly lower at the first cycle than the second cycle (0.99+/-0.45 hxmicrog/ml vs 1.34+/-0.65, respectively, P=0.027) whereas AUC of irinotecan and SN-38-glucuronide were higher at first cycle than second cycle (34.53+/-11.38 hxmicrog/ml vs. 28.42+/-12.23 hxmicrog/ml, P=0.064 and 2.39+/-1.21 h(microg/ml vs. 1.86+/-1.11 hxmicrog/ml, P=0.018, respectively).",Irinotecan in combination with thalidomide in patients with advanced solid tumors: a clinical study with pharmacodynamic and pharmacokinetic evaluation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16680463/),[h·μg] / [ml],34.53,15967,DB01041,Thalidomide
,16680463,AUC,"Indeed, area under the time-concentration curve (AUC) of SN-38 was significantly lower at the first cycle than the second cycle (0.99+/-0.45 hxmicrog/ml vs 1.34+/-0.65, respectively, P=0.027) whereas AUC of irinotecan and SN-38-glucuronide were higher at first cycle than second cycle (34.53+/-11.38 hxmicrog/ml vs. 28.42+/-12.23 hxmicrog/ml, P=0.064 and 2.39+/-1.21 h(microg/ml vs. 1.86+/-1.11 hxmicrog/ml, P=0.018, respectively).",Irinotecan in combination with thalidomide in patients with advanced solid tumors: a clinical study with pharmacodynamic and pharmacokinetic evaluation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16680463/),[h·μg] / [ml],28.42,15968,DB01041,Thalidomide
,16680463,AUC,"Indeed, area under the time-concentration curve (AUC) of SN-38 was significantly lower at the first cycle than the second cycle (0.99+/-0.45 hxmicrog/ml vs 1.34+/-0.65, respectively, P=0.027) whereas AUC of irinotecan and SN-38-glucuronide were higher at first cycle than second cycle (34.53+/-11.38 hxmicrog/ml vs. 28.42+/-12.23 hxmicrog/ml, P=0.064 and 2.39+/-1.21 h(microg/ml vs. 1.86+/-1.11 hxmicrog/ml, P=0.018, respectively).",Irinotecan in combination with thalidomide in patients with advanced solid tumors: a clinical study with pharmacodynamic and pharmacokinetic evaluation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16680463/),[h(μg] / [ml],2.39,15969,DB01041,Thalidomide
,16680463,AUC,"Indeed, area under the time-concentration curve (AUC) of SN-38 was significantly lower at the first cycle than the second cycle (0.99+/-0.45 hxmicrog/ml vs 1.34+/-0.65, respectively, P=0.027) whereas AUC of irinotecan and SN-38-glucuronide were higher at first cycle than second cycle (34.53+/-11.38 hxmicrog/ml vs. 28.42+/-12.23 hxmicrog/ml, P=0.064 and 2.39+/-1.21 h(microg/ml vs. 1.86+/-1.11 hxmicrog/ml, P=0.018, respectively).",Irinotecan in combination with thalidomide in patients with advanced solid tumors: a clinical study with pharmacodynamic and pharmacokinetic evaluation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16680463/),[h·μg] / [ml],1.86,15970,DB01041,Thalidomide
,24486861,extraction recovery,"Pomalidomide was stable in plasma through 4 freeze-thaw cycles (<12% change), in plasma at room temperature for up to 2h for samples not pre-stabilized with 0.1% HCl and up to 8h in samples pre-stabilized with 0.1% HCl, 24h post-preparation at 4°C (<2% change), and showed excellent extraction recovery (∼90%).",A sensitive and robust HPLC assay with fluorescence detection for the quantification of pomalidomide in human plasma for pharmacokinetic analyses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24486861/),%,∼90,20504,DB01041,Thalidomide
,24392952,ultrafiltration flow rates,"During in vitro hemodialysis with human blood (blood, dialysate, and ultrafiltration flow rates 250, 500 and 5 mL/min, respectively) comparing a highly permeable HCO dialyzer (Theralite, 2.1 m(2) ) to a high-flux dialyzer (PFX; 2.1 m(2) ), ultrafiltered volume was replaced by saline containing 30 g/L urea.",Clearance of drugs for multiple myeloma therapy during in vitro high-cutoff hemodialysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24392952/),[ml] / [min],250,25288,DB01041,Thalidomide
,24392952,ultrafiltration flow rates,"During in vitro hemodialysis with human blood (blood, dialysate, and ultrafiltration flow rates 250, 500 and 5 mL/min, respectively) comparing a highly permeable HCO dialyzer (Theralite, 2.1 m(2) ) to a high-flux dialyzer (PFX; 2.1 m(2) ), ultrafiltered volume was replaced by saline containing 30 g/L urea.",Clearance of drugs for multiple myeloma therapy during in vitro high-cutoff hemodialysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24392952/),[ml] / [min],500,25289,DB01041,Thalidomide
,24392952,ultrafiltration flow rates,"During in vitro hemodialysis with human blood (blood, dialysate, and ultrafiltration flow rates 250, 500 and 5 mL/min, respectively) comparing a highly permeable HCO dialyzer (Theralite, 2.1 m(2) ) to a high-flux dialyzer (PFX; 2.1 m(2) ), ultrafiltered volume was replaced by saline containing 30 g/L urea.",Clearance of drugs for multiple myeloma therapy during in vitro high-cutoff hemodialysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24392952/),[ml] / [min],5,25290,DB01041,Thalidomide
,24392952,Plasma K,"Plasma K values of HCO and PFX for THA, BOR, and DEX were about 40% (80 ± 7 vs. 65 ± 6 mL/min; P < 0.05), 70% (40 ± 8 vs. 33 ± 4 mL/min; P < 0.05), and 65% (47 ± 11 vs. 38 ± 7 mL/min; P < 0.05), respectively-lower (P < 0.0001) compared with urea (125 ± 7 vs. 122 ± 5 mL/min).",Clearance of drugs for multiple myeloma therapy during in vitro high-cutoff hemodialysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24392952/),%,40,25291,DB01041,Thalidomide
,24392952,Plasma K,"Plasma K values of HCO and PFX for THA, BOR, and DEX were about 40% (80 ± 7 vs. 65 ± 6 mL/min; P < 0.05), 70% (40 ± 8 vs. 33 ± 4 mL/min; P < 0.05), and 65% (47 ± 11 vs. 38 ± 7 mL/min; P < 0.05), respectively-lower (P < 0.0001) compared with urea (125 ± 7 vs. 122 ± 5 mL/min).",Clearance of drugs for multiple myeloma therapy during in vitro high-cutoff hemodialysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24392952/),[ml] / [min],80,25292,DB01041,Thalidomide
,24392952,Plasma K,"Plasma K values of HCO and PFX for THA, BOR, and DEX were about 40% (80 ± 7 vs. 65 ± 6 mL/min; P < 0.05), 70% (40 ± 8 vs. 33 ± 4 mL/min; P < 0.05), and 65% (47 ± 11 vs. 38 ± 7 mL/min; P < 0.05), respectively-lower (P < 0.0001) compared with urea (125 ± 7 vs. 122 ± 5 mL/min).",Clearance of drugs for multiple myeloma therapy during in vitro high-cutoff hemodialysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24392952/),[ml] / [min],65,25293,DB01041,Thalidomide
,24392952,Plasma K,"Plasma K values of HCO and PFX for THA, BOR, and DEX were about 40% (80 ± 7 vs. 65 ± 6 mL/min; P < 0.05), 70% (40 ± 8 vs. 33 ± 4 mL/min; P < 0.05), and 65% (47 ± 11 vs. 38 ± 7 mL/min; P < 0.05), respectively-lower (P < 0.0001) compared with urea (125 ± 7 vs. 122 ± 5 mL/min).",Clearance of drugs for multiple myeloma therapy during in vitro high-cutoff hemodialysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24392952/),%,70,25294,DB01041,Thalidomide
,24392952,Plasma K,"Plasma K values of HCO and PFX for THA, BOR, and DEX were about 40% (80 ± 7 vs. 65 ± 6 mL/min; P < 0.05), 70% (40 ± 8 vs. 33 ± 4 mL/min; P < 0.05), and 65% (47 ± 11 vs. 38 ± 7 mL/min; P < 0.05), respectively-lower (P < 0.0001) compared with urea (125 ± 7 vs. 122 ± 5 mL/min).",Clearance of drugs for multiple myeloma therapy during in vitro high-cutoff hemodialysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24392952/),[ml] / [min],40,25295,DB01041,Thalidomide
,24392952,Plasma K,"Plasma K values of HCO and PFX for THA, BOR, and DEX were about 40% (80 ± 7 vs. 65 ± 6 mL/min; P < 0.05), 70% (40 ± 8 vs. 33 ± 4 mL/min; P < 0.05), and 65% (47 ± 11 vs. 38 ± 7 mL/min; P < 0.05), respectively-lower (P < 0.0001) compared with urea (125 ± 7 vs. 122 ± 5 mL/min).",Clearance of drugs for multiple myeloma therapy during in vitro high-cutoff hemodialysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24392952/),[ml] / [min],33,25296,DB01041,Thalidomide
,24392952,Plasma K,"Plasma K values of HCO and PFX for THA, BOR, and DEX were about 40% (80 ± 7 vs. 65 ± 6 mL/min; P < 0.05), 70% (40 ± 8 vs. 33 ± 4 mL/min; P < 0.05), and 65% (47 ± 11 vs. 38 ± 7 mL/min; P < 0.05), respectively-lower (P < 0.0001) compared with urea (125 ± 7 vs. 122 ± 5 mL/min).",Clearance of drugs for multiple myeloma therapy during in vitro high-cutoff hemodialysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24392952/),%,65,25297,DB01041,Thalidomide
,24392952,Plasma K,"Plasma K values of HCO and PFX for THA, BOR, and DEX were about 40% (80 ± 7 vs. 65 ± 6 mL/min; P < 0.05), 70% (40 ± 8 vs. 33 ± 4 mL/min; P < 0.05), and 65% (47 ± 11 vs. 38 ± 7 mL/min; P < 0.05), respectively-lower (P < 0.0001) compared with urea (125 ± 7 vs. 122 ± 5 mL/min).",Clearance of drugs for multiple myeloma therapy during in vitro high-cutoff hemodialysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24392952/),[ml] / [min],47,25298,DB01041,Thalidomide
,24392952,Plasma K,"Plasma K values of HCO and PFX for THA, BOR, and DEX were about 40% (80 ± 7 vs. 65 ± 6 mL/min; P < 0.05), 70% (40 ± 8 vs. 33 ± 4 mL/min; P < 0.05), and 65% (47 ± 11 vs. 38 ± 7 mL/min; P < 0.05), respectively-lower (P < 0.0001) compared with urea (125 ± 7 vs. 122 ± 5 mL/min).",Clearance of drugs for multiple myeloma therapy during in vitro high-cutoff hemodialysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24392952/),[ml] / [min],38,25299,DB01041,Thalidomide
,24392952,Plasma K,"Plasma K values of HCO and PFX for THA, BOR, and DEX were about 40% (80 ± 7 vs. 65 ± 6 mL/min; P < 0.05), 70% (40 ± 8 vs. 33 ± 4 mL/min; P < 0.05), and 65% (47 ± 11 vs. 38 ± 7 mL/min; P < 0.05), respectively-lower (P < 0.0001) compared with urea (125 ± 7 vs. 122 ± 5 mL/min).",Clearance of drugs for multiple myeloma therapy during in vitro high-cutoff hemodialysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24392952/),[ml] / [min],125,25300,DB01041,Thalidomide
,24392952,Plasma K,"Plasma K values of HCO and PFX for THA, BOR, and DEX were about 40% (80 ± 7 vs. 65 ± 6 mL/min; P < 0.05), 70% (40 ± 8 vs. 33 ± 4 mL/min; P < 0.05), and 65% (47 ± 11 vs. 38 ± 7 mL/min; P < 0.05), respectively-lower (P < 0.0001) compared with urea (125 ± 7 vs. 122 ± 5 mL/min).",Clearance of drugs for multiple myeloma therapy during in vitro high-cutoff hemodialysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24392952/),[ml] / [min],122,25301,DB01041,Thalidomide
,24392952,PBF,"Compared with BOR and DEX (minimum 72 and 56%, respectively), the PBF of THA (37%) was significantly lower (P < 0.001).",Clearance of drugs for multiple myeloma therapy during in vitro high-cutoff hemodialysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24392952/),%,37,25302,DB01041,Thalidomide
,33016014,Cmax,"Cmax (fasted, 1.34 ± 0.12 μg/mL; fed, 2.47 ± 0.19 μg/mL) and Tmax (fasted, 3 h; fed, 10 h) differed substantially between the 2 groups.",Pharmacokinetics of thalidomide in dogs: can feeding affect it? A preliminary study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33016014/),[μg] / [ml],1.34,29858,DB01041,Thalidomide
,33016014,Cmax,"Cmax (fasted, 1.34 ± 0.12 μg/mL; fed, 2.47 ± 0.19 μg/mL) and Tmax (fasted, 3 h; fed, 10 h) differed substantially between the 2 groups.",Pharmacokinetics of thalidomide in dogs: can feeding affect it? A preliminary study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33016014/),[μg] / [ml],2.47,29859,DB01041,Thalidomide
,33016014,Tmax,"Cmax (fasted, 1.34 ± 0.12 μg/mL; fed, 2.47 ± 0.19 μg/mL) and Tmax (fasted, 3 h; fed, 10 h) differed substantially between the 2 groups.",Pharmacokinetics of thalidomide in dogs: can feeding affect it? A preliminary study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33016014/),h,3,29860,DB01041,Thalidomide
,33016014,Tmax,"Cmax (fasted, 1.34 ± 0.12 μg/mL; fed, 2.47 ± 0.19 μg/mL) and Tmax (fasted, 3 h; fed, 10 h) differed substantially between the 2 groups.",Pharmacokinetics of thalidomide in dogs: can feeding affect it? A preliminary study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33016014/),h,10,29861,DB01041,Thalidomide
,33016014,AUC,AUC and t1/2λz were significantly higher in fed (42.46 ± 6.64 mg × h/L; 17.14 ± 4.68 h) compared to fasted (12.38 ± 1.13 mg × h/L; 6.55 ± 1.25 h) dogs.,Pharmacokinetics of thalidomide in dogs: can feeding affect it? A preliminary study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33016014/),[h·mg] / [l],42.46,29862,DB01041,Thalidomide
,33016014,AUC,AUC and t1/2λz were significantly higher in fed (42.46 ± 6.64 mg × h/L; 17.14 ± 4.68 h) compared to fasted (12.38 ± 1.13 mg × h/L; 6.55 ± 1.25 h) dogs.,Pharmacokinetics of thalidomide in dogs: can feeding affect it? A preliminary study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33016014/),[h·mg] / [l],12.38,29863,DB01041,Thalidomide
,33016014,t1/2λz,AUC and t1/2λz were significantly higher in fed (42.46 ± 6.64 mg × h/L; 17.14 ± 4.68 h) compared to fasted (12.38 ± 1.13 mg × h/L; 6.55 ± 1.25 h) dogs.,Pharmacokinetics of thalidomide in dogs: can feeding affect it? A preliminary study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/33016014/),h,17.14,29864,DB01041,Thalidomide
,33016014,t1/2λz,AUC and t1/2λz were significantly higher in fed (42.46 ± 6.64 mg × h/L; 17.14 ± 4.68 h) compared to fasted (12.38 ± 1.13 mg × h/L; 6.55 ± 1.25 h) dogs.,Pharmacokinetics of thalidomide in dogs: can feeding affect it? A preliminary study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/33016014/),h,6.55,29865,DB01041,Thalidomide
,33016014,relative oral bioavailability,The relative oral bioavailability of TAL for the fasted group was low (36.92% ± 3.28%).,Pharmacokinetics of thalidomide in dogs: can feeding affect it? A preliminary study. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33016014/),%,36.92,29866,DB01041,Thalidomide
,26337806,T max,Ixazomib was rapidly absorbed with a median T max of 1.5 h on day 1 and 2.0 h on day 15 of cycle 1 and had a geometric mean terminal half-life of 6.1 days.,Pharmacokinetics and safety of ixazomib plus lenalidomide-dexamethasone in Asian patients with relapsed/refractory myeloma: a phase 1 study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26337806/),h,1.5,33350,DB01041,Thalidomide
,26337806,T max,Ixazomib was rapidly absorbed with a median T max of 1.5 h on day 1 and 2.0 h on day 15 of cycle 1 and had a geometric mean terminal half-life of 6.1 days.,Pharmacokinetics and safety of ixazomib plus lenalidomide-dexamethasone in Asian patients with relapsed/refractory myeloma: a phase 1 study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26337806/),h,2.0,33351,DB01041,Thalidomide
,26337806,terminal half-life,Ixazomib was rapidly absorbed with a median T max of 1.5 h on day 1 and 2.0 h on day 15 of cycle 1 and had a geometric mean terminal half-life of 6.1 days.,Pharmacokinetics and safety of ixazomib plus lenalidomide-dexamethasone in Asian patients with relapsed/refractory myeloma: a phase 1 study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26337806/),d,6.1,33352,DB01041,Thalidomide
,2492686,half-life,"The half-life of racemic EM 12 and of the two enantiomers in vitro (phosphate buffer pH 7.4, 37 degrees C) were all in the same range (12 h).","The enantiomers of the teratogenic thalidomide analogue EM 12. 2. Chemical stability, stereoselectivity of metabolism and renal excretion in the marmoset monkey. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2492686/),h,12,39564,DB01041,Thalidomide
,10461824,absorption half-life,"The drug was rapidly absorbed, with a mean absorption half-life of 0.95 hr (range, 0.16-2.49 hr) and 1.19 hr (range, 0.33-3.53 hr) after 100- and 200-mg doses, respectively.",Pharmacokinetics and hemodynamic effects of single oral doses of thalidomide in asymptomatic human immunodeficiency virus-infected subjects. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10461824/),h,0.95,41636,DB01041,Thalidomide
,10461824,absorption half-life,"The drug was rapidly absorbed, with a mean absorption half-life of 0.95 hr (range, 0.16-2.49 hr) and 1.19 hr (range, 0.33-3.53 hr) after 100- and 200-mg doses, respectively.",Pharmacokinetics and hemodynamic effects of single oral doses of thalidomide in asymptomatic human immunodeficiency virus-infected subjects. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10461824/),h,1.19,41637,DB01041,Thalidomide
,10461824,Cmax,"The corresponding mean Cmax values were 1.15+/-0.24 microg/ml (100 mg) and 1.92+/-0.47 microg/ml (200 mg; p<0.001), which were achieved (Tmax) at 2.5+/-1.5 h and 3.3+/-1.4 hr, respectively.",Pharmacokinetics and hemodynamic effects of single oral doses of thalidomide in asymptomatic human immunodeficiency virus-infected subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10461824/),[μg] / [ml],1.15,41638,DB01041,Thalidomide
,10461824,Cmax,"The corresponding mean Cmax values were 1.15+/-0.24 microg/ml (100 mg) and 1.92+/-0.47 microg/ml (200 mg; p<0.001), which were achieved (Tmax) at 2.5+/-1.5 h and 3.3+/-1.4 hr, respectively.",Pharmacokinetics and hemodynamic effects of single oral doses of thalidomide in asymptomatic human immunodeficiency virus-infected subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10461824/),[μg] / [ml],1.92,41639,DB01041,Thalidomide
,10461824,Tmax,"The corresponding mean Cmax values were 1.15+/-0.24 microg/ml (100 mg) and 1.92+/-0.47 microg/ml (200 mg; p<0.001), which were achieved (Tmax) at 2.5+/-1.5 h and 3.3+/-1.4 hr, respectively.",Pharmacokinetics and hemodynamic effects of single oral doses of thalidomide in asymptomatic human immunodeficiency virus-infected subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10461824/),h,2.5,41640,DB01041,Thalidomide
,10461824,Tmax,"The corresponding mean Cmax values were 1.15+/-0.24 microg/ml (100 mg) and 1.92+/-0.47 microg/ml (200 mg; p<0.001), which were achieved (Tmax) at 2.5+/-1.5 h and 3.3+/-1.4 hr, respectively.",Pharmacokinetics and hemodynamic effects of single oral doses of thalidomide in asymptomatic human immunodeficiency virus-infected subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10461824/),h,3.3,41641,DB01041,Thalidomide
,10461824,elimination half-lives,"Plasma concentrations of thalidomide declined thereafter, in a log-linear manner, with elimination half-lives of 4.6+/-1.2 hr (100 mg) and 5.3+/-2.2 hr (200 mg).",Pharmacokinetics and hemodynamic effects of single oral doses of thalidomide in asymptomatic human immunodeficiency virus-infected subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10461824/),h,4.6,41642,DB01041,Thalidomide
,10461824,elimination half-lives,"Plasma concentrations of thalidomide declined thereafter, in a log-linear manner, with elimination half-lives of 4.6+/-1.2 hr (100 mg) and 5.3+/-2.2 hr (200 mg).",Pharmacokinetics and hemodynamic effects of single oral doses of thalidomide in asymptomatic human immunodeficiency virus-infected subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10461824/),h,5.3,41643,DB01041,Thalidomide
,10461824,apparent volumes of distribution (Vdss/F),"The apparent volumes of distribution (Vdss/F) were 69.9+/-15.6 liters (100 mg) and 82.7+/-34.9 liters (200 mg) while total body clearances (Cl/F) were 10.4+/-2.1 and 10.8+/-1.7 liters/hr, respectively.",Pharmacokinetics and hemodynamic effects of single oral doses of thalidomide in asymptomatic human immunodeficiency virus-infected subjects. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10461824/),l,69.9,41644,DB01041,Thalidomide
,10461824,apparent volumes of distribution (Vdss/F),"The apparent volumes of distribution (Vdss/F) were 69.9+/-15.6 liters (100 mg) and 82.7+/-34.9 liters (200 mg) while total body clearances (Cl/F) were 10.4+/-2.1 and 10.8+/-1.7 liters/hr, respectively.",Pharmacokinetics and hemodynamic effects of single oral doses of thalidomide in asymptomatic human immunodeficiency virus-infected subjects. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10461824/),l,82.7,41645,DB01041,Thalidomide
,10461824,total body clearances (Cl/F),"The apparent volumes of distribution (Vdss/F) were 69.9+/-15.6 liters (100 mg) and 82.7+/-34.9 liters (200 mg) while total body clearances (Cl/F) were 10.4+/-2.1 and 10.8+/-1.7 liters/hr, respectively.",Pharmacokinetics and hemodynamic effects of single oral doses of thalidomide in asymptomatic human immunodeficiency virus-infected subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10461824/),[l] / [h],10.4,41646,DB01041,Thalidomide
,10461824,total body clearances (Cl/F),"The apparent volumes of distribution (Vdss/F) were 69.9+/-15.6 liters (100 mg) and 82.7+/-34.9 liters (200 mg) while total body clearances (Cl/F) were 10.4+/-2.1 and 10.8+/-1.7 liters/hr, respectively.",Pharmacokinetics and hemodynamic effects of single oral doses of thalidomide in asymptomatic human immunodeficiency virus-infected subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10461824/),[l] / [h],10.8,41647,DB01041,Thalidomide
,15080764,protein binding,"Thalidomide interconverts between the (R)- and (S)-enantiomers in plasma, with protein binding of 55% and 65%, respectively.",Clinical pharmacokinetics of thalidomide. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15080764/),,55,47836,DB01041,Thalidomide
,15080764,protein binding,"Thalidomide interconverts between the (R)- and (S)-enantiomers in plasma, with protein binding of 55% and 65%, respectively.",Clinical pharmacokinetics of thalidomide. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15080764/),,65,47837,DB01041,Thalidomide
,15080764,peak concentration (C(max)),"After a single oral dose of thalidomide 200 mg (as the US-approved capsule formulation) in healthy volunteers, absorption is slow and extensive, resulting in a peak concentration (C(max)) of 1-2 mg/L at 3-4 hours after administration, absorption lag time of 30 minutes, total exposure (AUC( infinity )) of 18 mg.",Clinical pharmacokinetics of thalidomide. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15080764/),[mg] / [l],1-2,47838,DB01041,Thalidomide
,15080764,absorption lag time,"After a single oral dose of thalidomide 200 mg (as the US-approved capsule formulation) in healthy volunteers, absorption is slow and extensive, resulting in a peak concentration (C(max)) of 1-2 mg/L at 3-4 hours after administration, absorption lag time of 30 minutes, total exposure (AUC( infinity )) of 18 mg.",Clinical pharmacokinetics of thalidomide. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15080764/),min,30,47839,DB01041,Thalidomide
,15080764,total exposure (AUC( infinity )),"After a single oral dose of thalidomide 200 mg (as the US-approved capsule formulation) in healthy volunteers, absorption is slow and extensive, resulting in a peak concentration (C(max)) of 1-2 mg/L at 3-4 hours after administration, absorption lag time of 30 minutes, total exposure (AUC( infinity )) of 18 mg.",Clinical pharmacokinetics of thalidomide. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15080764/),mg,18,47840,DB01041,Thalidomide
,15080764,apparent elimination half-life,"h/L, apparent elimination half-life of 6 hours and apparent systemic clearance of 10 L/h.",Clinical pharmacokinetics of thalidomide. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15080764/),h,6,47841,DB01041,Thalidomide
,15080764,apparent systemic clearance,"h/L, apparent elimination half-life of 6 hours and apparent systemic clearance of 10 L/h.",Clinical pharmacokinetics of thalidomide. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15080764/),[l] / [h],10,47842,DB01041,Thalidomide
,15080764,apparent elimination half-life,"The apparent elimination half-life of 6 hours therefore represents absorption, not elimination.",Clinical pharmacokinetics of thalidomide. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15080764/),h,6,47843,DB01041,Thalidomide
,15080764,apparent volume of distribution,The 'true' apparent volume of distribution was estimated to be 16L by use of the faster elimination-rate half-life.,Clinical pharmacokinetics of thalidomide. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15080764/),l,16,47844,DB01041,Thalidomide
,15080764,steady-state C(max) (C(ss)(max)),"Multiple doses of thalidomide 200 mg/day over 21 days cause no change in the pharmacokinetics, with a steady-state C(max) (C(ss)(max)) of 1.2 mg/L.",Clinical pharmacokinetics of thalidomide. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15080764/),[mg] / [l],1.2,47845,DB01041,Thalidomide
,15080764,C(ss)(max),"Simulation of 400 and 800 mg/day also shows no accumulation, with C(ss)(max) of 3.5 and 6.0 mg/L, respectively.",Clinical pharmacokinetics of thalidomide. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15080764/),[mg] / [l],3.5,47846,DB01041,Thalidomide
,15080764,C(ss)(max),"Simulation of 400 and 800 mg/day also shows no accumulation, with C(ss)(max) of 3.5 and 6.0 mg/L, respectively.",Clinical pharmacokinetics of thalidomide. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15080764/),[mg] / [l],6.0,47847,DB01041,Thalidomide
,23316845,flow rate,"After a simple protein precipitation using methanol, LND and carbamazepine (IS) were separated on Acquity UPLC BEH™ C18 column (50 × 2.1 mm, i.d. 1.7 μm, Waters, USA) using a mobile phase consisted of acetonitrile:water:formic acid (65:35:0.1%, v/v/v) pumped at a flow rate of 0.2 mL/min.",Development and validation of ultra-performance liquid chromatographic method with tandem mass spectrometry for determination of lenalidomide in rabbit and human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23316845/),[ml] / [min],0.2,51317,DB01041,Thalidomide
,23316845,m/z,"The precursor to product ion transitions of m/z 260.1 > 149.0 and m/z 237.0 > 179.0 were used to quantify LND and IS, respectively.",Development and validation of ultra-performance liquid chromatographic method with tandem mass spectrometry for determination of lenalidomide in rabbit and human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23316845/),,260.1,51318,DB01041,Thalidomide
>,23316845,m/z,"The precursor to product ion transitions of m/z 260.1 > 149.0 and m/z 237.0 > 179.0 were used to quantify LND and IS, respectively.",Development and validation of ultra-performance liquid chromatographic method with tandem mass spectrometry for determination of lenalidomide in rabbit and human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23316845/),,149.0,51319,DB01041,Thalidomide
>,23316845,m/z,"The precursor to product ion transitions of m/z 260.1 > 149.0 and m/z 237.0 > 179.0 were used to quantify LND and IS, respectively.",Development and validation of ultra-performance liquid chromatographic method with tandem mass spectrometry for determination of lenalidomide in rabbit and human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23316845/),,237.0,51320,DB01041,Thalidomide
>,23316845,m/z,"The precursor to product ion transitions of m/z 260.1 > 149.0 and m/z 237.0 > 179.0 were used to quantify LND and IS, respectively.",Development and validation of ultra-performance liquid chromatographic method with tandem mass spectrometry for determination of lenalidomide in rabbit and human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23316845/),,179.0,51321,DB01041,Thalidomide
,25502411,ΔG(‡),"The enantiomerization barrier ΔG(‡) was determined to be 98.3 ± 1.0 kJ/mol; the activation parameters ΔH(‡) = 46.1 ± 2.4 kJ/mol and ΔS(‡) = -170 ± 61 J/(K·mol) for EM12 and ΔG(‡) = 91.5 ± 1.0 kJ/mol, ΔH(‡) = 62.4 ± 5.4 kJ/mol, and ΔS(‡) = -98 ± 7 J/(K·mol) for lenalidomide.",Investigation of the enantiomerization barriers of the phthalimidone derivatives EM12 and lenalidomide by dynamic electrokinetic chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25502411/),[kj] / [mol],98.3,53431,DB01041,Thalidomide
,25502411,ΔH(‡),"The enantiomerization barrier ΔG(‡) was determined to be 98.3 ± 1.0 kJ/mol; the activation parameters ΔH(‡) = 46.1 ± 2.4 kJ/mol and ΔS(‡) = -170 ± 61 J/(K·mol) for EM12 and ΔG(‡) = 91.5 ± 1.0 kJ/mol, ΔH(‡) = 62.4 ± 5.4 kJ/mol, and ΔS(‡) = -98 ± 7 J/(K·mol) for lenalidomide.",Investigation of the enantiomerization barriers of the phthalimidone derivatives EM12 and lenalidomide by dynamic electrokinetic chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25502411/),[kj] / [mol],46.1,53432,DB01041,Thalidomide
,25502411,ΔS(‡),"The enantiomerization barrier ΔG(‡) was determined to be 98.3 ± 1.0 kJ/mol; the activation parameters ΔH(‡) = 46.1 ± 2.4 kJ/mol and ΔS(‡) = -170 ± 61 J/(K·mol) for EM12 and ΔG(‡) = 91.5 ± 1.0 kJ/mol, ΔH(‡) = 62.4 ± 5.4 kJ/mol, and ΔS(‡) = -98 ± 7 J/(K·mol) for lenalidomide.",Investigation of the enantiomerization barriers of the phthalimidone derivatives EM12 and lenalidomide by dynamic electrokinetic chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25502411/),[j] / [k·mol],-170,53433,DB01041,Thalidomide
,25502411,ΔG(‡),"The enantiomerization barrier ΔG(‡) was determined to be 98.3 ± 1.0 kJ/mol; the activation parameters ΔH(‡) = 46.1 ± 2.4 kJ/mol and ΔS(‡) = -170 ± 61 J/(K·mol) for EM12 and ΔG(‡) = 91.5 ± 1.0 kJ/mol, ΔH(‡) = 62.4 ± 5.4 kJ/mol, and ΔS(‡) = -98 ± 7 J/(K·mol) for lenalidomide.",Investigation of the enantiomerization barriers of the phthalimidone derivatives EM12 and lenalidomide by dynamic electrokinetic chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25502411/),[kj] / [mol],91.5,53434,DB01041,Thalidomide
,25502411,ΔH(‡),"The enantiomerization barrier ΔG(‡) was determined to be 98.3 ± 1.0 kJ/mol; the activation parameters ΔH(‡) = 46.1 ± 2.4 kJ/mol and ΔS(‡) = -170 ± 61 J/(K·mol) for EM12 and ΔG(‡) = 91.5 ± 1.0 kJ/mol, ΔH(‡) = 62.4 ± 5.4 kJ/mol, and ΔS(‡) = -98 ± 7 J/(K·mol) for lenalidomide.",Investigation of the enantiomerization barriers of the phthalimidone derivatives EM12 and lenalidomide by dynamic electrokinetic chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25502411/),[kj] / [mol],62.4,53435,DB01041,Thalidomide
,25502411,ΔS(‡),"The enantiomerization barrier ΔG(‡) was determined to be 98.3 ± 1.0 kJ/mol; the activation parameters ΔH(‡) = 46.1 ± 2.4 kJ/mol and ΔS(‡) = -170 ± 61 J/(K·mol) for EM12 and ΔG(‡) = 91.5 ± 1.0 kJ/mol, ΔH(‡) = 62.4 ± 5.4 kJ/mol, and ΔS(‡) = -98 ± 7 J/(K·mol) for lenalidomide.",Investigation of the enantiomerization barriers of the phthalimidone derivatives EM12 and lenalidomide by dynamic electrokinetic chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25502411/),[j] / [k·mol],-98,53436,DB01041,Thalidomide
<,20160158,maximal drug content,The maximal drug content in a single ejaculate was <2000 ng (<0.01% of the daily 25-mg dose).,Distribution of lenalidomide into semen of healthy men after multiple oral doses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20160158/),ng,2000,61318,DB01041,Thalidomide
,12201491,maximum tolerated dose (MTD),"The maximum tolerated dose (MTD) in mouse, rabbit, rat and human was 30, 99, 330, and 99 mg/kg respectively.","5,6-dimethylxanthenone-4-acetic acid (DMXAA): a new biological response modifier for cancer therapy. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12201491/),[mg] / [kg],30,63682,DB01041,Thalidomide
,12201491,maximum tolerated dose (MTD),"The maximum tolerated dose (MTD) in mouse, rabbit, rat and human was 30, 99, 330, and 99 mg/kg respectively.","5,6-dimethylxanthenone-4-acetic acid (DMXAA): a new biological response modifier for cancer therapy. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12201491/),[mg] / [kg],99,63683,DB01041,Thalidomide
,12201491,maximum tolerated dose (MTD),"The maximum tolerated dose (MTD) in mouse, rabbit, rat and human was 30, 99, 330, and 99 mg/kg respectively.","5,6-dimethylxanthenone-4-acetic acid (DMXAA): a new biological response modifier for cancer therapy. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12201491/),[mg] / [kg],330,63684,DB01041,Thalidomide
,2571480,peak concentration,"The mean (+/- SD) peak concentration, 1.15 +/- 0.2 microgram/ml, was achieved at 4.39 +/- 1.27 hr.",Plasma pharmacokinetics and urinary excretion of thalidomide after oral dosing in healthy male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2571480/),[μg] / [ml],1.15,65456,DB01041,Thalidomide
,2571480,Absorption,"Absorption and elimination half-lives were 1.70 +/- 1.05 hr and 8.70 +/- 4.11 hr, respectively, with a lag time of 0.41 +/- 0.17 hr observed in six subjects.",Plasma pharmacokinetics and urinary excretion of thalidomide after oral dosing in healthy male volunteers. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2571480/),h,1.70,65457,DB01041,Thalidomide
,2571480,elimination half-lives,"Absorption and elimination half-lives were 1.70 +/- 1.05 hr and 8.70 +/- 4.11 hr, respectively, with a lag time of 0.41 +/- 0.17 hr observed in six subjects.",Plasma pharmacokinetics and urinary excretion of thalidomide after oral dosing in healthy male volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2571480/),h,8.70,65458,DB01041,Thalidomide
,2571480,lag time,"Absorption and elimination half-lives were 1.70 +/- 1.05 hr and 8.70 +/- 4.11 hr, respectively, with a lag time of 0.41 +/- 0.17 hr observed in six subjects.",Plasma pharmacokinetics and urinary excretion of thalidomide after oral dosing in healthy male volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2571480/),h,0.41,65459,DB01041,Thalidomide
,2571480,apparent volume of distribution,"The apparent volume of distribution and total body clearance rate, based on assumed complete bioavailability, were 120.69 +/- 45.36 liters and 10.41 +/- 2.04 liters/hr.",Plasma pharmacokinetics and urinary excretion of thalidomide after oral dosing in healthy male volunteers. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2571480/),l,120.69,65460,DB01041,Thalidomide
,2571480,total body clearance rate,"The apparent volume of distribution and total body clearance rate, based on assumed complete bioavailability, were 120.69 +/- 45.36 liters and 10.41 +/- 2.04 liters/hr.",Plasma pharmacokinetics and urinary excretion of thalidomide after oral dosing in healthy male volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2571480/),[l] / [h],10.41,65461,DB01041,Thalidomide
,2571480,renal clearance rate,"The urinary excretion of thalidomide accounted for only 0.6 +/- 0.22% of the total dose administered over 24 hr, and the renal clearance rate was 0.08 +/- 0.03 liter/hr.",Plasma pharmacokinetics and urinary excretion of thalidomide after oral dosing in healthy male volunteers. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2571480/),[l] / [h],0.08,65462,DB01041,Thalidomide
,23203815,recovery,"Mean recovery was 88 %, with 73 and 15 % of the radioactive dose excreted in urine and feces, respectively, indicating good oral absorption.","Absorption, metabolism and excretion of [14C]pomalidomide in humans following oral administration. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23203815/),%,88,68843,DB01041,Thalidomide
,23203815,recovery,"Mean recovery was 88 %, with 73 and 15 % of the radioactive dose excreted in urine and feces, respectively, indicating good oral absorption.","Absorption, metabolism and excretion of [14C]pomalidomide in humans following oral administration. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23203815/),%,73,68844,DB01041,Thalidomide
,23203815,recovery,"Mean recovery was 88 %, with 73 and 15 % of the radioactive dose excreted in urine and feces, respectively, indicating good oral absorption.","Absorption, metabolism and excretion of [14C]pomalidomide in humans following oral administration. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23203815/),%,15,68845,DB01041,Thalidomide
,23203815,C(max),"Mean C(max), AUC(0-∞) and t(max) values for pomalidomide in plasma were 13 ng/mL, 189 ng*h/mL and 3.0 h.","Absorption, metabolism and excretion of [14C]pomalidomide in humans following oral administration. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23203815/),[ng] / [ml],13,68846,DB01041,Thalidomide
,23203815,AUC(0-∞),"Mean C(max), AUC(0-∞) and t(max) values for pomalidomide in plasma were 13 ng/mL, 189 ng*h/mL and 3.0 h.","Absorption, metabolism and excretion of [14C]pomalidomide in humans following oral administration. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23203815/),[h·ng] / [ml],189,68847,DB01041,Thalidomide
,23203815,t(max),"Mean C(max), AUC(0-∞) and t(max) values for pomalidomide in plasma were 13 ng/mL, 189 ng*h/mL and 3.0 h.","Absorption, metabolism and excretion of [14C]pomalidomide in humans following oral administration. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23203815/),h,3.0,68848,DB01041,Thalidomide
,23203815,terminal half-lives,"Radioactivity and pomalidomide were rapidly cleared from circulation, with terminal half-lives of 8.9 and 11.2 h.","Absorption, metabolism and excretion of [14C]pomalidomide in humans following oral administration. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23203815/),h,8.9,68849,DB01041,Thalidomide
,23203815,terminal half-lives,"Radioactivity and pomalidomide were rapidly cleared from circulation, with terminal half-lives of 8.9 and 11.2 h.","Absorption, metabolism and excretion of [14C]pomalidomide in humans following oral administration. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23203815/),h,11.2,68850,DB01041,Thalidomide
,22955172,time to C (max) (t (max)),"Co-administration with a high-fat meal reduced the area under the concentration-time curve (AUC) and C (max) by approximately 20 and 50 %, respectively, and delayed time to C (max) (t (max)) by 1.63 h.","Single-dose pharmacokinetics of lenalidomide in healthy volunteers: dose proportionality, food effect, and racial sensitivity. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22955172/),h,1.63,71582,DB01041,Thalidomide
,22955172,terminal elimination half-life (t (½)),The terminal elimination half-life (t (½)) was 3-4 h at doses up to 50 mg and was not affected by food.,"Single-dose pharmacokinetics of lenalidomide in healthy volunteers: dose proportionality, food effect, and racial sensitivity. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22955172/),h,3-4,71583,DB01041,Thalidomide
,16736151,Maximum semaximib plasma concentration,Maximum semaximib plasma concentration values were 1.2-3.8 microg/ml in course 1 and 1.1-3.9 microg/ml in course 2.,"A phase II, pharmacokinetic, and biologic study of semaxanib and thalidomide in patients with metastatic melanoma. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16736151/),[μg] / [ml],1.2-3.8,72835,DB01041,Thalidomide
,16736151,Maximum semaximib plasma concentration,Maximum semaximib plasma concentration values were 1.2-3.8 microg/ml in course 1 and 1.1-3.9 microg/ml in course 2.,"A phase II, pharmacokinetic, and biologic study of semaxanib and thalidomide in patients with metastatic melanoma. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16736151/),[μg] / [ml],1.1-3.9,72836,DB01041,Thalidomide
,16736151,terminal half-life,The mean terminal half-life was 1.3 ( +/- 0.31) h.,"A phase II, pharmacokinetic, and biologic study of semaxanib and thalidomide in patients with metastatic melanoma. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16736151/),h,1.3,72837,DB01041,Thalidomide
,25621435,flow rate,"Chromatographic separation was carried on Acquity BEH™ C18 column (50mm×2.1mm, 1.7μm) using an isocratic mobile phase of acetonitrile: 10mM ammonium acetate (80:20, v/v), at a flow rate of 0.250mL/min.",A validated UPLC-MS/MS assay using negative ionization mode for high-throughput determination of pomalidomide in rat plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25621435/),[ml] / [min],0.250,86531,DB01041,Thalidomide
,25621435,total run time,"Both pomalidomide and IS were eluted at 0.66±0.03 and 0.80±0.03min, respectively, with a total run time of 1.5min only.",A validated UPLC-MS/MS assay using negative ionization mode for high-throughput determination of pomalidomide in rat plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25621435/),min,1.5,86532,DB01041,Thalidomide
,25621435,m,"The precursor to product ion transitions of m/z 272.01→160.89 for pomalidomide and m/z 380.08→316.01 for IS were used to quantify them respectively, multiple reaction monitoring mode.",A validated UPLC-MS/MS assay using negative ionization mode for high-throughput determination of pomalidomide in rat plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25621435/),,272.01,86533,DB01041,Thalidomide
,9420064,peak concentrations,"Single doses of thalidomide were well absorbed, with mean peak concentrations (+/- standard deviations) of 1.17 +/- 0.21 and 3.47 +/- 1.14 microg/ml in the 100- and 300-mg dosing groups, respectively, and the mean elimination half-life was approximately 6 h.",Single-dose pharmacokinetics of thalidomide in human immunodeficiency virus-infected patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9420064/),[μg] / [ml],1.17,90622,DB01041,Thalidomide
,9420064,peak concentrations,"Single doses of thalidomide were well absorbed, with mean peak concentrations (+/- standard deviations) of 1.17 +/- 0.21 and 3.47 +/- 1.14 microg/ml in the 100- and 300-mg dosing groups, respectively, and the mean elimination half-life was approximately 6 h.",Single-dose pharmacokinetics of thalidomide in human immunodeficiency virus-infected patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9420064/),[μg] / [ml],3.47,90623,DB01041,Thalidomide
,9420064,elimination half-life,"Single doses of thalidomide were well absorbed, with mean peak concentrations (+/- standard deviations) of 1.17 +/- 0.21 and 3.47 +/- 1.14 microg/ml in the 100- and 300-mg dosing groups, respectively, and the mean elimination half-life was approximately 6 h.",Single-dose pharmacokinetics of thalidomide in human immunodeficiency virus-infected patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9420064/),h,6,90624,DB01041,Thalidomide
,27988790,area under the curve,"According to our model, the area under the curve was 3273 µg h/L, i.e., 60% higher than expected under usual dosage (25 mg q.d.) with normal renal function.",Pharmacokinetics of lenalidomide during high cut-off dialysis in a patient with multiple myeloma and renal failure. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27988790/),[h·μg] / [l],3273,91471,DB01041,Thalidomide
,31326409,overall response rate,The overall response rate was 70.6%.,"Oprozomib, pomalidomide, and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31326409/),%,70.6,99008,DB01041,Thalidomide
,10972483,elimination half-life (t1/2),"Coadministration of thalidomide to Colon 38 tumour-bearing mice significantly (P < 0.05) increased the elimination half-life (t1/2) of DMXAA in plasma (413 micromol/l), liver (132 micromol/l), and spleen (77 micromol/l), and significantly (P < 0.05) increased DMXAA concentrations in Colon 38 tumour tissue (0.25-4.5 h).","Modulation of the pharmacokinetics of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in mice by thalidomide. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10972483/),[μM] / [l],413,99350,DB01041,Thalidomide
,10972483,elimination half-life (t1/2),"Coadministration of thalidomide to Colon 38 tumour-bearing mice significantly (P < 0.05) increased the elimination half-life (t1/2) of DMXAA in plasma (413 micromol/l), liver (132 micromol/l), and spleen (77 micromol/l), and significantly (P < 0.05) increased DMXAA concentrations in Colon 38 tumour tissue (0.25-4.5 h).","Modulation of the pharmacokinetics of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in mice by thalidomide. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10972483/),[μM] / [l],132,99351,DB01041,Thalidomide
,10972483,elimination half-life (t1/2),"Coadministration of thalidomide to Colon 38 tumour-bearing mice significantly (P < 0.05) increased the elimination half-life (t1/2) of DMXAA in plasma (413 micromol/l), liver (132 micromol/l), and spleen (77 micromol/l), and significantly (P < 0.05) increased DMXAA concentrations in Colon 38 tumour tissue (0.25-4.5 h).","Modulation of the pharmacokinetics of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in mice by thalidomide. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10972483/),[μM] / [l],77,99352,DB01041,Thalidomide
,30880967,EE,"The optimized nanoparticles (F3) had particles size 307.3±8.5 nm with a low PDI value 0.317, ZP of -43.4±2.6 mV, EE of 61.1±1.9% and DL of 1.9±0.1%.",Preparation of sustained release apremilast-loaded PLGA nanoparticles: in vitro characterization and in vivo pharmacokinetic study in rats. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30880967/),%,61.1,101448,DB01041,Thalidomide
,30880967,DL,"The optimized nanoparticles (F3) had particles size 307.3±8.5 nm with a low PDI value 0.317, ZP of -43.4±2.6 mV, EE of 61.1±1.9% and DL of 1.9±0.1%.",Preparation of sustained release apremilast-loaded PLGA nanoparticles: in vitro characterization and in vivo pharmacokinetic study in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30880967/),%,1.9,101449,DB01041,Thalidomide
,14578685,survival,The median survival was 3.6 months.,Phase II trial and pharmacokinetic study of thalidomide in patients with metastatic colorectal cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14578685/),month,3.6,102668,DB01041,Thalidomide
,24463402,flow rate,"Analytes were recovered by liquid-liquid extraction and separated on a reverse phase C18 column (150mm×4.6mm i.d., 5μm) using methanol:0.1% formic acid buffer (70:30) as mobile phase at a flow rate of 1mL/min in isocratic mode.","Simultaneous quantification of idelalisib, fludarabine and lenalidomide in rat plasma by using high-performance liquid chromatography coupled with heated electrospray ionization tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24463402/),[ml] / [min],1,103646,DB01041,Thalidomide
,22956478,systemic bioavailability,"Administration of 0.5 and 10 mg/kg resulted in systemic bioavailability ranges of 90-105% and 60-75% via IP and oral routes, respectively.",Pharmacokinetics and tissue disposition of lenalidomide in mice. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22956478/),%,90-105,115790,DB01041,Thalidomide
,22956478,systemic bioavailability,"Administration of 0.5 and 10 mg/kg resulted in systemic bioavailability ranges of 90-105% and 60-75% via IP and oral routes, respectively.",Pharmacokinetics and tissue disposition of lenalidomide in mice. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22956478/),%,60-75,115791,DB01041,Thalidomide
<,18056189,time to tumor progression,"In the group of 24 patients with recurrent glioblastoma, the median time to tumor progression was <2 months and only 12.5% of patients were progression-free at 6 months.",A phase I trial of lenalidomide in patients with recurrent primary central nervous system tumors. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18056189/),month,2,125862,DB01041,Thalidomide
,34431670,oral bioavailability,"ARD-2128 achieves 67% oral bioavailability in mice, effectively reduces AR protein and suppresses AR-regulated genes in tumor tissues with oral administration, leading to the effective inhibition of tumor growth in mice without signs of toxicity.",Strategies toward Discovery of Potent and Orally Bioavailable Proteolysis Targeting Chimera Degraders of Androgen Receptor for the Treatment of Prostate Cancer. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34431670/),%,67,126565,DB01041,Thalidomide
,20956622,Response duration,Response duration ranged from 5.6 to 14 months.,Dose escalation of lenalidomide in relapsed or refractory acute leukemias. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20956622/),month,5.6 to 14,128705,DB01041,Thalidomide
,3143339,plasma elimination half-life,"The mean plasma elimination half-life was in the range of 5 h for the enantiomers, as well as for the racemic mixture, although there was a tendency toward slower elimination and higher plasma AUC values of the S-enantiomer: thus, after administration of the (greater than 99%) pure enantiomers, the plasma AUC value of the administered S-enantiomer was found to be more than one-third higher than that of the administered R-enantiomer.",The enantiomers of the teratogenic thalidomide analogue EM 12: 1. Chiral inversion and plasma pharmacokinetics in the marmoset monkey. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3143339/),h,5,130244,DB01041,Thalidomide
,26292221,time to response,"Responses (partial response or better) were achieved by three patients (25%; 1 [17%] in Cohort 1 and 2 [33%] in Cohort 2), and the median time to response was 6.4 months overall (9.0 months for Cohort 1 and 4.2 months for Cohort 2).",Pomalidomide alone or in combination with dexamethasone in Japanese patients with refractory or relapsed and refractory multiple myeloma. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26292221/),month,6.4,133348,DB01041,Thalidomide
,26292221,time to response,"Responses (partial response or better) were achieved by three patients (25%; 1 [17%] in Cohort 1 and 2 [33%] in Cohort 2), and the median time to response was 6.4 months overall (9.0 months for Cohort 1 and 4.2 months for Cohort 2).",Pomalidomide alone or in combination with dexamethasone in Japanese patients with refractory or relapsed and refractory multiple myeloma. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26292221/),month,9.0,133349,DB01041,Thalidomide
,26292221,time to response,"Responses (partial response or better) were achieved by three patients (25%; 1 [17%] in Cohort 1 and 2 [33%] in Cohort 2), and the median time to response was 6.4 months overall (9.0 months for Cohort 1 and 4.2 months for Cohort 2).",Pomalidomide alone or in combination with dexamethasone in Japanese patients with refractory or relapsed and refractory multiple myeloma. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26292221/),month,4.2,133350,DB01041,Thalidomide
,26292221,progression-free survival,The median progression-free survival was 5.5 months overall (5.1 months for Cohort 1 and not reached for Cohort 2).,Pomalidomide alone or in combination with dexamethasone in Japanese patients with refractory or relapsed and refractory multiple myeloma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26292221/),month,5.5,133351,DB01041,Thalidomide
,26292221,progression-free survival,The median progression-free survival was 5.5 months overall (5.1 months for Cohort 1 and not reached for Cohort 2).,Pomalidomide alone or in combination with dexamethasone in Japanese patients with refractory or relapsed and refractory multiple myeloma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26292221/),month,5.1,133352,DB01041,Thalidomide
,18827465,maximum plasma concentration,"The pharmacokinetic profiles of Japanese and British capsules were similar, while the 100 mg Japanese thalidomide capsule demonstrated a 1.6-fold higher maximum plasma concentration than the 200 mg Mexican thalidomide tablet (1.7 vs. 1.1 microg/ml), greatly shortened t(max) (4.5 vs. 6.2 h), and the apparent half life was only one-third of the Mexican tablet (4.8 vs. 13.5 h).","[Comparison of dissolution profile and plasma concentration-time profile of the thalidomide formulations made by Japanese, Mexican and British companies]. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18827465/),[μg] / [ml],1.7,136690,DB01041,Thalidomide
,18827465,maximum plasma concentration,"The pharmacokinetic profiles of Japanese and British capsules were similar, while the 100 mg Japanese thalidomide capsule demonstrated a 1.6-fold higher maximum plasma concentration than the 200 mg Mexican thalidomide tablet (1.7 vs. 1.1 microg/ml), greatly shortened t(max) (4.5 vs. 6.2 h), and the apparent half life was only one-third of the Mexican tablet (4.8 vs. 13.5 h).","[Comparison of dissolution profile and plasma concentration-time profile of the thalidomide formulations made by Japanese, Mexican and British companies]. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18827465/),[μg] / [ml],1.1,136691,DB01041,Thalidomide
,18827465,t(max),"The pharmacokinetic profiles of Japanese and British capsules were similar, while the 100 mg Japanese thalidomide capsule demonstrated a 1.6-fold higher maximum plasma concentration than the 200 mg Mexican thalidomide tablet (1.7 vs. 1.1 microg/ml), greatly shortened t(max) (4.5 vs. 6.2 h), and the apparent half life was only one-third of the Mexican tablet (4.8 vs. 13.5 h).","[Comparison of dissolution profile and plasma concentration-time profile of the thalidomide formulations made by Japanese, Mexican and British companies]. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18827465/),h,4.5,136692,DB01041,Thalidomide
,18827465,t(max),"The pharmacokinetic profiles of Japanese and British capsules were similar, while the 100 mg Japanese thalidomide capsule demonstrated a 1.6-fold higher maximum plasma concentration than the 200 mg Mexican thalidomide tablet (1.7 vs. 1.1 microg/ml), greatly shortened t(max) (4.5 vs. 6.2 h), and the apparent half life was only one-third of the Mexican tablet (4.8 vs. 13.5 h).","[Comparison of dissolution profile and plasma concentration-time profile of the thalidomide formulations made by Japanese, Mexican and British companies]. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18827465/),h,6.2,136693,DB01041,Thalidomide
,18827465,apparent half life,"The pharmacokinetic profiles of Japanese and British capsules were similar, while the 100 mg Japanese thalidomide capsule demonstrated a 1.6-fold higher maximum plasma concentration than the 200 mg Mexican thalidomide tablet (1.7 vs. 1.1 microg/ml), greatly shortened t(max) (4.5 vs. 6.2 h), and the apparent half life was only one-third of the Mexican tablet (4.8 vs. 13.5 h).","[Comparison of dissolution profile and plasma concentration-time profile of the thalidomide formulations made by Japanese, Mexican and British companies]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18827465/),h,4.8,136694,DB01041,Thalidomide
,18827465,apparent half life,"The pharmacokinetic profiles of Japanese and British capsules were similar, while the 100 mg Japanese thalidomide capsule demonstrated a 1.6-fold higher maximum plasma concentration than the 200 mg Mexican thalidomide tablet (1.7 vs. 1.1 microg/ml), greatly shortened t(max) (4.5 vs. 6.2 h), and the apparent half life was only one-third of the Mexican tablet (4.8 vs. 13.5 h).","[Comparison of dissolution profile and plasma concentration-time profile of the thalidomide formulations made by Japanese, Mexican and British companies]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18827465/),h,13.5,136695,DB01041,Thalidomide
,17964516,peak response,"The peak response for TNF-alpha was 1.5 h, 2.5 h for IL-8, and 3.0 h for IL-6.",Thalidomide suppressed interleukin-6 but not tumor necrosis factor-alpha in volunteers with experimental endotoxemia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17964516/),h,1.5,137930,DB01041,Thalidomide
,17964516,peak response,"The peak response for TNF-alpha was 1.5 h, 2.5 h for IL-8, and 3.0 h for IL-6.",Thalidomide suppressed interleukin-6 but not tumor necrosis factor-alpha in volunteers with experimental endotoxemia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17964516/),h,2.5,137931,DB01041,Thalidomide
,17964516,peak response,"The peak response for TNF-alpha was 1.5 h, 2.5 h for IL-8, and 3.0 h for IL-6.",Thalidomide suppressed interleukin-6 but not tumor necrosis factor-alpha in volunteers with experimental endotoxemia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17964516/),h,3.0,137932,DB01041,Thalidomide
,24962564,"overall exposure (AUC(0,∞))","Ketoconazole increases overall exposure (AUC(0,∞)) of apremilast by ≈36% (2827 vs. 2072 ng ml(-1) h, 90% CI = 126.2, 147.5) and peak exposure (Cmax ) by 5% (247 vs. 236 ng ml(-1) ).",The impact of co-administration of ketoconazole and rifampicin on the pharmacokinetics of apremilast in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24962564/),[h·ng] / [ml],2827,139737,DB01041,Thalidomide
,24962564,"overall exposure (AUC(0,∞))","Ketoconazole increases overall exposure (AUC(0,∞)) of apremilast by ≈36% (2827 vs. 2072 ng ml(-1) h, 90% CI = 126.2, 147.5) and peak exposure (Cmax ) by 5% (247 vs. 236 ng ml(-1) ).",The impact of co-administration of ketoconazole and rifampicin on the pharmacokinetics of apremilast in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24962564/),[h·ng] / [ml],2072,139738,DB01041,Thalidomide
,24962564,peak exposure (Cmax ),"Ketoconazole increases overall exposure (AUC(0,∞)) of apremilast by ≈36% (2827 vs. 2072 ng ml(-1) h, 90% CI = 126.2, 147.5) and peak exposure (Cmax ) by 5% (247 vs. 236 ng ml(-1) ).",The impact of co-administration of ketoconazole and rifampicin on the pharmacokinetics of apremilast in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24962564/),[ng] / [ml],247,139739,DB01041,Thalidomide
,24962564,peak exposure (Cmax ),"Ketoconazole increases overall exposure (AUC(0,∞)) of apremilast by ≈36% (2827 vs. 2072 ng ml(-1) h, 90% CI = 126.2, 147.5) and peak exposure (Cmax ) by 5% (247 vs. 236 ng ml(-1) ).",The impact of co-administration of ketoconazole and rifampicin on the pharmacokinetics of apremilast in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24962564/),[ng] / [ml],236,139740,DB01041,Thalidomide
,24962564,"AUC(0,∞)","Multiple doses of rifampicin increase apremilast clearance ≈3.6-fold and decrease apremilast mean AUC(0,∞) by ≈72% (3120 vs. 869 ng ml(-1) h, 90% CI = 25.7, 30.4) and Cmax (from 290 vs.",The impact of co-administration of ketoconazole and rifampicin on the pharmacokinetics of apremilast in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24962564/),[h·ng] / [ml],869,139741,DB01041,Thalidomide
,24962564,Cmax,"Multiple doses of rifampicin increase apremilast clearance ≈3.6-fold and decrease apremilast mean AUC(0,∞) by ≈72% (3120 vs. 869 ng ml(-1) h, 90% CI = 25.7, 30.4) and Cmax (from 290 vs.",The impact of co-administration of ketoconazole and rifampicin on the pharmacokinetics of apremilast in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24962564/),,290,139742,DB01041,Thalidomide
,24962564,"AUC(0,∞))","A 30 min intravenous infusion of rifampicin 600 mg had negligible effects on the overall exposure (AUC(0,∞)) of apremilast (2980 vs. 3120 ng ml(-1) h, 90% CI = 88.0, 104.1).",The impact of co-administration of ketoconazole and rifampicin on the pharmacokinetics of apremilast in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24962564/),[h·ng] / [ml],2980,139743,DB01041,Thalidomide
,24962564,"AUC(0,∞))","A 30 min intravenous infusion of rifampicin 600 mg had negligible effects on the overall exposure (AUC(0,∞)) of apremilast (2980 vs. 3120 ng ml(-1) h, 90% CI = 88.0, 104.1).",The impact of co-administration of ketoconazole and rifampicin on the pharmacokinetics of apremilast in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24962564/),[h·ng] / [ml],3120,139744,DB01041,Thalidomide
,33932093,maximum concentration,"Apremilast was rapidly absorbed (maximum concentration: ~2-3 h postdose), and eliminated according to a monoexponential pattern with a terminal-phase elimination half-life of 8-9 h.",Pharmacokinetics and tolerability of apremilast in healthy Korean adult men. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33932093/),h,2-3,141165,DB01041,Thalidomide
,33932093,terminal-phase elimination half-life,"Apremilast was rapidly absorbed (maximum concentration: ~2-3 h postdose), and eliminated according to a monoexponential pattern with a terminal-phase elimination half-life of 8-9 h.",Pharmacokinetics and tolerability of apremilast in healthy Korean adult men. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/33932093/),h,8-9,141166,DB01041,Thalidomide
,19406727,concentrations,"The mean concentrations at 100 mg/day and 200 mg/day were 0.343 microg/mL (range, 0.05-1.45 microg/mL) and 0.875 microg/mL (range, 0.19-2.09 microg/mL), respectively.",A pharmacokinetic study evaluating the relationship between treatment efficacy and incidence of adverse events with thalidomide plasma concentrations in patients with refractory multiple myeloma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19406727/),[μg] / [ml],0.343,142658,DB01041,Thalidomide
,19406727,concentrations,"The mean concentrations at 100 mg/day and 200 mg/day were 0.343 microg/mL (range, 0.05-1.45 microg/mL) and 0.875 microg/mL (range, 0.19-2.09 microg/mL), respectively.",A pharmacokinetic study evaluating the relationship between treatment efficacy and incidence of adverse events with thalidomide plasma concentrations in patients with refractory multiple myeloma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19406727/),[μg] / [ml],0.875,142659,DB01041,Thalidomide
,19406727,overall response rate,The overall response rate (near-complete response + partial response + minimal response) of this treatment was 73%.,A pharmacokinetic study evaluating the relationship between treatment efficacy and incidence of adverse events with thalidomide plasma concentrations in patients with refractory multiple myeloma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19406727/),%,73,142660,DB01041,Thalidomide
,11583477,oral clearance,"Thalidomide oral clearance averaged 0.14 +/- 0.08 and 0.12 +/- 0.05 l/h/kg on weeks 1 and 4 (p = 0.72), while the terminal elimination half-life averaged 5.7 +/- 1.5 and 7.3 +/- 1.7 hours (p = 0.12).",Pharmacokinetics and pharmacodynamics of thalidomide in HIV patients treated for oral aphthous ulcers: ACTG protocol 251. AIDS Clinical Trials Group. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11583477/),[l] / [h·kg],0.14,144789,DB01041,Thalidomide
,11583477,oral clearance,"Thalidomide oral clearance averaged 0.14 +/- 0.08 and 0.12 +/- 0.05 l/h/kg on weeks 1 and 4 (p = 0.72), while the terminal elimination half-life averaged 5.7 +/- 1.5 and 7.3 +/- 1.7 hours (p = 0.12).",Pharmacokinetics and pharmacodynamics of thalidomide in HIV patients treated for oral aphthous ulcers: ACTG protocol 251. AIDS Clinical Trials Group. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11583477/),[l] / [h·kg],0.12,144790,DB01041,Thalidomide
,11583477,terminal elimination half-life,"Thalidomide oral clearance averaged 0.14 +/- 0.08 and 0.12 +/- 0.05 l/h/kg on weeks 1 and 4 (p = 0.72), while the terminal elimination half-life averaged 5.7 +/- 1.5 and 7.3 +/- 1.7 hours (p = 0.12).",Pharmacokinetics and pharmacodynamics of thalidomide in HIV patients treated for oral aphthous ulcers: ACTG protocol 251. AIDS Clinical Trials Group. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11583477/),h,5.7,144791,DB01041,Thalidomide
,11583477,terminal elimination half-life,"Thalidomide oral clearance averaged 0.14 +/- 0.08 and 0.12 +/- 0.05 l/h/kg on weeks 1 and 4 (p = 0.72), while the terminal elimination half-life averaged 5.7 +/- 1.5 and 7.3 +/- 1.7 hours (p = 0.12).",Pharmacokinetics and pharmacodynamics of thalidomide in HIV patients treated for oral aphthous ulcers: ACTG protocol 251. AIDS Clinical Trials Group. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11583477/),h,7.3,144792,DB01041,Thalidomide
,11583477,time-averaged trough,"The median time-averaged trough value for subjects deemed complete responders was 0.60, while the median value for noncomplete responders was 0.54.",Pharmacokinetics and pharmacodynamics of thalidomide in HIV patients treated for oral aphthous ulcers: ACTG protocol 251. AIDS Clinical Trials Group. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11583477/),,0.60,144793,DB01041,Thalidomide
,11583477,time-averaged trough,"The median time-averaged trough value for subjects deemed complete responders was 0.60, while the median value for noncomplete responders was 0.54.",Pharmacokinetics and pharmacodynamics of thalidomide in HIV patients treated for oral aphthous ulcers: ACTG protocol 251. AIDS Clinical Trials Group. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11583477/),,0.54,144794,DB01041,Thalidomide
,22936658,response rate,"Among 39 patients, HI-E response rate to monotherapy was 86% (6 of 7) in del(5q) and 25% (8 of 32) in non-del(5q) patients (10 mg, 17.7%; 15 mg, 33.3%).",Combined treatment with lenalidomide and epoetin alfa in lower-risk patients with myelodysplastic syndrome. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22936658/),%,86,150736,DB01041,Thalidomide
,22936658,response rate,"Among 39 patients, HI-E response rate to monotherapy was 86% (6 of 7) in del(5q) and 25% (8 of 32) in non-del(5q) patients (10 mg, 17.7%; 15 mg, 33.3%).",Combined treatment with lenalidomide and epoetin alfa in lower-risk patients with myelodysplastic syndrome. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22936658/),%,25,150737,DB01041,Thalidomide
,22109830,apparent clearance (Cl/F),"For thalidomide, the median apparent clearance (Cl/F) was 2.9 mL/min/kg, the median plasma AUC was 80 μM h, and the median terminal half-life (t(½)) was 13.3 h.",Plasma and cerebrospinal fluid pharmacokinetics of thalidomide and lenalidomide in nonhuman primates. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22109830/),[ml] / [kg·min],2.9,158779,DB01041,Thalidomide
,22109830,plasma AUC,"For thalidomide, the median apparent clearance (Cl/F) was 2.9 mL/min/kg, the median plasma AUC was 80 μM h, and the median terminal half-life (t(½)) was 13.3 h.",Plasma and cerebrospinal fluid pharmacokinetics of thalidomide and lenalidomide in nonhuman primates. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22109830/),h·μM,80,158780,DB01041,Thalidomide
,22109830,terminal half-life (t(½)),"For thalidomide, the median apparent clearance (Cl/F) was 2.9 mL/min/kg, the median plasma AUC was 80 μM h, and the median terminal half-life (t(½)) was 13.3 h.",Plasma and cerebrospinal fluid pharmacokinetics of thalidomide and lenalidomide in nonhuman primates. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22109830/),h,13.3,158781,DB01041,Thalidomide
,22109830,Cl/F,"For lenalidomide, the median Cl/F was 8.7 mL/min/kg, the median AUC was 9 μM h, and the median t(½) was 5.6 h.",Plasma and cerebrospinal fluid pharmacokinetics of thalidomide and lenalidomide in nonhuman primates. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22109830/),[ml] / [kg·min],8.7,158782,DB01041,Thalidomide
,22109830,AUC,"For lenalidomide, the median Cl/F was 8.7 mL/min/kg, the median AUC was 9 μM h, and the median t(½) was 5.6 h.",Plasma and cerebrospinal fluid pharmacokinetics of thalidomide and lenalidomide in nonhuman primates. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22109830/),h·μM,9,158783,DB01041,Thalidomide
,22109830,t(½),"For lenalidomide, the median Cl/F was 8.7 mL/min/kg, the median AUC was 9 μM h, and the median t(½) was 5.6 h.",Plasma and cerebrospinal fluid pharmacokinetics of thalidomide and lenalidomide in nonhuman primates. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22109830/),h,5.6,158784,DB01041,Thalidomide
,22109830,penetration,"Thalidomide was detected in the CSF of all animals, with a median penetration of 42%.",Plasma and cerebrospinal fluid pharmacokinetics of thalidomide and lenalidomide in nonhuman primates. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22109830/),%,42,158785,DB01041,Thalidomide
,22109830,penetration,"Lenalidomide was detected in the CSF of 2 of 3 animals, with a CSF penetration of 11% in each.",Plasma and cerebrospinal fluid pharmacokinetics of thalidomide and lenalidomide in nonhuman primates. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22109830/),%,11,158786,DB01041,Thalidomide
,9499573,plasma protein binding,"The geometric mean plasma protein binding was 55% and 66%, respectively, for (+)-(R)- and (-)-(S)-thalidomide.",Enantiomers of thalidomide: blood distribution and the influence of serum albumin on chiral inversion and hydrolysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9499573/),%,55,159497,DB01041,Thalidomide
,9499573,plasma protein binding,"The geometric mean plasma protein binding was 55% and 66%, respectively, for (+)-(R)- and (-)-(S)-thalidomide.",Enantiomers of thalidomide: blood distribution and the influence of serum albumin on chiral inversion and hydrolysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9499573/),%,66,159498,DB01041,Thalidomide
,28000099,T max,"Ixazomib was rapidly absorbed with a median T max of approximately 1-2-h post-dose, and had a geometric mean terminal half-life of 5-6 days.",Phase 1 study of ixazomib alone or combined with lenalidomide-dexamethasone in Japanese patients with relapsed/refractory multiple myeloma. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28000099/),h,1-2-,164685,DB01041,Thalidomide
,28000099,terminal half-life,"Ixazomib was rapidly absorbed with a median T max of approximately 1-2-h post-dose, and had a geometric mean terminal half-life of 5-6 days.",Phase 1 study of ixazomib alone or combined with lenalidomide-dexamethasone in Japanese patients with relapsed/refractory multiple myeloma. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28000099/),d,5-6,164686,DB01041,Thalidomide
,6890834,half-lives,Excretion rates of urinary radioactivity show a 2-phase course with half-lives of 2.6 h and 10 h.,The metabolic fate of supidimide in the rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6890834/),h,2.6,168274,DB01041,Thalidomide
,6890834,half-lives,Excretion rates of urinary radioactivity show a 2-phase course with half-lives of 2.6 h and 10 h.,The metabolic fate of supidimide in the rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6890834/),h,10,168275,DB01041,Thalidomide
,6890834,half-life,Unchanged supidimide is eliminated with a half-life of 2.1 h.,The metabolic fate of supidimide in the rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6890834/),h,2.1,168276,DB01041,Thalidomide
,23404219,flow rate,"The analyte and internal standard were extracted by liquid-liquid extraction with ether-dichloromethane (3:2, v/v) and separated on a TC-C(18) column using methanol-10 mM ammonium acetate-formic acid (60:40:0.04, v/v/v) as the mobile phase at a flow rate of 0.9 ml/min.",Determination of thalidomide concentration in human plasma by liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23404219/),[ml] / [min],0.9,171865,DB01041,Thalidomide
,23404219,m/z,The multiple reaction monitoring (MRM) transitions were m/z 259.1→84.0 for the analyte and m/z 195.9→138.9 for temozolomide.,Determination of thalidomide concentration in human plasma by liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23404219/),,259.1,171866,DB01041,Thalidomide
,23404219,m/z,The multiple reaction monitoring (MRM) transitions were m/z 259.1→84.0 for the analyte and m/z 195.9→138.9 for temozolomide.,Determination of thalidomide concentration in human plasma by liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23404219/),,195.9,171867,DB01041,Thalidomide
,23404219,m/z,The multiple reaction monitoring (MRM) transitions were m/z 259.1→84.0 for the analyte and m/z 195.9→138.9 for temozolomide.,Determination of thalidomide concentration in human plasma by liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23404219/),,138.9,171868,DB01041,Thalidomide
,1036887,half-life,"The half-life of imidan, detected in the exterioized fetuses or in newborns, was 50--70 min.",Metabolic and toxic behavior of phthalimide derivates. I. Fate of imidan in the fetus. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1036887/),min,50--70,173807,DB01041,Thalidomide
,18282676,run time,T and IS were detected at UV wavelength of 220nm with a run time of 10min.,High performance liquid chromatographic determination of thalidomide in patients affected by hepatocellular carcinoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18282676/),min,10,176614,DB01041,Thalidomide
,18282676,flow rate,"Mobile phase was 10mM pH 5.5NH4+CH3COO-/CH3CN, 75/25 (v/v) buffer at flow rate of 1.5ml/min.",High performance liquid chromatographic determination of thalidomide in patients affected by hepatocellular carcinoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18282676/),[ml] / [min],1.5,176615,DB01041,Thalidomide
,26727254,T1/2,"Following I/V administration, T1/2 was 5.0 (SEM 0.4) hours, volume of distribution was 3,372.0 (SEM 244.3) mL/kg and clearance was 487.1 (SEM 46.1) mL/hour.",Thalidomide pharmacokinetics in sheep. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26727254/),h,5.0,178007,DB01041,Thalidomide
,26727254,volume of distribution,"Following I/V administration, T1/2 was 5.0 (SEM 0.4) hours, volume of distribution was 3,372.0 (SEM 244.3) mL/kg and clearance was 487.1 (SEM 46.1) mL/hour.",Thalidomide pharmacokinetics in sheep. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26727254/),[ml] / [kg],"3,372.0",178008,DB01041,Thalidomide
,26727254,clearance,"Following I/V administration, T1/2 was 5.0 (SEM 0.4) hours, volume of distribution was 3,372.0 (SEM 244.3) mL/kg and clearance was 487.1 (SEM 46.1) mL/hour.",Thalidomide pharmacokinetics in sheep. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26727254/),[ml] / [h],487.1,178009,DB01041,Thalidomide
,26727254,bioavailability,"Following oral administration, thalidomide bioavailability was 89%, with T1/2, Tmax, and Cmax being 7.2 (SEM 0.8) hours, 3.0 (SEM 0.4) hours and 1,767.3 (SEM 178.1) ng/mL, respectively.",Thalidomide pharmacokinetics in sheep. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26727254/),%,89,178010,DB01041,Thalidomide
,26727254,T1/2,"Following oral administration, thalidomide bioavailability was 89%, with T1/2, Tmax, and Cmax being 7.2 (SEM 0.8) hours, 3.0 (SEM 0.4) hours and 1,767.3 (SEM 178.1) ng/mL, respectively.",Thalidomide pharmacokinetics in sheep. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26727254/),h,7.2,178011,DB01041,Thalidomide
,26727254,Tmax,"Following oral administration, thalidomide bioavailability was 89%, with T1/2, Tmax, and Cmax being 7.2 (SEM 0.8) hours, 3.0 (SEM 0.4) hours and 1,767.3 (SEM 178.1) ng/mL, respectively.",Thalidomide pharmacokinetics in sheep. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26727254/),h,3.0,178012,DB01041,Thalidomide
,26727254,Cmax,"Following oral administration, thalidomide bioavailability was 89%, with T1/2, Tmax, and Cmax being 7.2 (SEM 0.8) hours, 3.0 (SEM 0.4) hours and 1,767.3 (SEM 178.1) ng/mL, respectively.",Thalidomide pharmacokinetics in sheep. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26727254/),[ng] / [ml],"1,767.3",178013,DB01041,Thalidomide
,26727254,T1/2,"The mean pharmacokinetic parameters determined following oral treatment with 400 mg of thalidomide were similar to those reported in humans receiving a single 400 mg oral dose (T1/2 7.3 hours; Tmax 4.3 hours and Cmax 2,820 ng/mL).",Thalidomide pharmacokinetics in sheep. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26727254/),h,7.3,178014,DB01041,Thalidomide
,26727254,Tmax,"The mean pharmacokinetic parameters determined following oral treatment with 400 mg of thalidomide were similar to those reported in humans receiving a single 400 mg oral dose (T1/2 7.3 hours; Tmax 4.3 hours and Cmax 2,820 ng/mL).",Thalidomide pharmacokinetics in sheep. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26727254/),h,4.3,178015,DB01041,Thalidomide
,26727254,Cmax,"The mean pharmacokinetic parameters determined following oral treatment with 400 mg of thalidomide were similar to those reported in humans receiving a single 400 mg oral dose (T1/2 7.3 hours; Tmax 4.3 hours and Cmax 2,820 ng/mL).",Thalidomide pharmacokinetics in sheep. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26727254/),[ng] / [ml],"2,820",178016,DB01041,Thalidomide
,10933131,terminal half-lives,Inter-individual variation in the disposition of the enantiomers was modest (e.g. terminal half-lives ranged between 3.9 and 5.3h).,Intravenous formulations of the enantiomers of thalidomide: pharmacokinetic and initial pharmacodynamic characterization in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10933131/),h,3.9 and 5.3,178358,DB01041,Thalidomide
,16085147,flow rate,"Mobile phase consisted of acetonitrile-10 mM ammonium acetate buffer (pH 5.50) (28:72, v/v), at a flow rate of 0.8 ml/min.",Determination of thalidomide by high performance liquid chromatography: plasma pharmacokinetic studies in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16085147/),[ml] / [min],0.8,178372,DB01041,Thalidomide
,12487149,plasma clearance,"In contrast, allometric scaling using in vivo data from the mouse, rat, and rabbit predicted a plasma clearance of 3.5 mL/min/kg, similar to that observed in patients (3.7 mL/min/kg).","Predicting pharmacokinetics and drug interactions in patients from in vitro and in vivo models: the experience with 5,6-dimethylxanthenone-4-acetic acid (DMXAA), an anti-cancer drug eliminated mainly by conjugation. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12487149/),[ml] / [kg·min],3.5,181457,DB01041,Thalidomide
,12487149,plasma clearance,"In contrast, allometric scaling using in vivo data from the mouse, rat, and rabbit predicted a plasma clearance of 3.5 mL/min/kg, similar to that observed in patients (3.7 mL/min/kg).","Predicting pharmacokinetics and drug interactions in patients from in vitro and in vivo models: the experience with 5,6-dimethylxanthenone-4-acetic acid (DMXAA), an anti-cancer drug eliminated mainly by conjugation. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12487149/),[ml] / [kg·min],3.7,181458,DB01041,Thalidomide
,16520988,MTD,The MTD of twice-daily schedule was determined as 300 mg/day.,Phase I and pharmacokinetic study of oral thalidomide in patients with advanced hepatocellular carcinoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16520988/),[mg] / [d],300,181736,DB01041,Thalidomide
,22271472,overall survival,"Median overall survival, progression-free survival, and overall response rate were 15.3 months, 7.4 months, and 35.0%, respectively, for patients in the PC arm, in comparison with 16.0 months (P = .99), 7.8 months (P = .96), and 38.2% (P = .47), respectively, for patients in the TPC arm.",Randomized phase III study of thoracic radiation in combination with paclitaxel and carboplatin with or without thalidomide in patients with stage III non-small-cell lung cancer: the ECOG 3598 study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22271472/),month,15.3,183279,DB01041,Thalidomide
,22271472,progression-free survival,"Median overall survival, progression-free survival, and overall response rate were 15.3 months, 7.4 months, and 35.0%, respectively, for patients in the PC arm, in comparison with 16.0 months (P = .99), 7.8 months (P = .96), and 38.2% (P = .47), respectively, for patients in the TPC arm.",Randomized phase III study of thoracic radiation in combination with paclitaxel and carboplatin with or without thalidomide in patients with stage III non-small-cell lung cancer: the ECOG 3598 study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22271472/),month,7.4,183280,DB01041,Thalidomide
,22271472,progression-free survival,"Median overall survival, progression-free survival, and overall response rate were 15.3 months, 7.4 months, and 35.0%, respectively, for patients in the PC arm, in comparison with 16.0 months (P = .99), 7.8 months (P = .96), and 38.2% (P = .47), respectively, for patients in the TPC arm.",Randomized phase III study of thoracic radiation in combination with paclitaxel and carboplatin with or without thalidomide in patients with stage III non-small-cell lung cancer: the ECOG 3598 study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22271472/),%,35.0,183281,DB01041,Thalidomide
,22271472,progression-free survival,"Median overall survival, progression-free survival, and overall response rate were 15.3 months, 7.4 months, and 35.0%, respectively, for patients in the PC arm, in comparison with 16.0 months (P = .99), 7.8 months (P = .96), and 38.2% (P = .47), respectively, for patients in the TPC arm.",Randomized phase III study of thoracic radiation in combination with paclitaxel and carboplatin with or without thalidomide in patients with stage III non-small-cell lung cancer: the ECOG 3598 study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22271472/),month,16.0,183282,DB01041,Thalidomide
,22271472,progression-free survival,"Median overall survival, progression-free survival, and overall response rate were 15.3 months, 7.4 months, and 35.0%, respectively, for patients in the PC arm, in comparison with 16.0 months (P = .99), 7.8 months (P = .96), and 38.2% (P = .47), respectively, for patients in the TPC arm.",Randomized phase III study of thoracic radiation in combination with paclitaxel and carboplatin with or without thalidomide in patients with stage III non-small-cell lung cancer: the ECOG 3598 study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22271472/),month,7.8,183283,DB01041,Thalidomide
,22271472,progression-free survival,"Median overall survival, progression-free survival, and overall response rate were 15.3 months, 7.4 months, and 35.0%, respectively, for patients in the PC arm, in comparison with 16.0 months (P = .99), 7.8 months (P = .96), and 38.2% (P = .47), respectively, for patients in the TPC arm.",Randomized phase III study of thoracic radiation in combination with paclitaxel and carboplatin with or without thalidomide in patients with stage III non-small-cell lung cancer: the ECOG 3598 study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22271472/),%,38.2,183284,DB01041,Thalidomide
,22271472,overall response rate,"Median overall survival, progression-free survival, and overall response rate were 15.3 months, 7.4 months, and 35.0%, respectively, for patients in the PC arm, in comparison with 16.0 months (P = .99), 7.8 months (P = .96), and 38.2% (P = .47), respectively, for patients in the TPC arm.",Randomized phase III study of thoracic radiation in combination with paclitaxel and carboplatin with or without thalidomide in patients with stage III non-small-cell lung cancer: the ECOG 3598 study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22271472/),%,35.0,183285,DB01041,Thalidomide
,22271472,overall response rate,"Median overall survival, progression-free survival, and overall response rate were 15.3 months, 7.4 months, and 35.0%, respectively, for patients in the PC arm, in comparison with 16.0 months (P = .99), 7.8 months (P = .96), and 38.2% (P = .47), respectively, for patients in the TPC arm.",Randomized phase III study of thoracic radiation in combination with paclitaxel and carboplatin with or without thalidomide in patients with stage III non-small-cell lung cancer: the ECOG 3598 study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22271472/),month,7.8,183286,DB01041,Thalidomide
,22271472,overall response rate,"Median overall survival, progression-free survival, and overall response rate were 15.3 months, 7.4 months, and 35.0%, respectively, for patients in the PC arm, in comparison with 16.0 months (P = .99), 7.8 months (P = .96), and 38.2% (P = .47), respectively, for patients in the TPC arm.",Randomized phase III study of thoracic radiation in combination with paclitaxel and carboplatin with or without thalidomide in patients with stage III non-small-cell lung cancer: the ECOG 3598 study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22271472/),%,38.2,183287,DB01041,Thalidomide
,26795075,CrCl,"The median baseline CrCl was 105 mL/min (range, 84-146 mL/min) for those with NRF and 26 mL/min (range, 15-33 mL/min) for those with SRI.",Pharmacokinetics and Safety of Elotuzumab Combined With Lenalidomide and Dexamethasone in Patients With Multiple Myeloma and Various Levels of Renal Impairment: Results of a Phase Ib Study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26795075/),[ml] / [min],105,184705,DB01041,Thalidomide
,26795075,CrCl,"The median baseline CrCl was 105 mL/min (range, 84-146 mL/min) for those with NRF and 26 mL/min (range, 15-33 mL/min) for those with SRI.",Pharmacokinetics and Safety of Elotuzumab Combined With Lenalidomide and Dexamethasone in Patients With Multiple Myeloma and Various Levels of Renal Impairment: Results of a Phase Ib Study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26795075/),[ml] / [min],26,184706,DB01041,Thalidomide
,26795075,overall response rates,"The overall response rates were 75% in the NRF, 67% in the SRI, and 56% in the ESRD groups.",Pharmacokinetics and Safety of Elotuzumab Combined With Lenalidomide and Dexamethasone in Patients With Multiple Myeloma and Various Levels of Renal Impairment: Results of a Phase Ib Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26795075/),%,75,184707,DB01041,Thalidomide
,26795075,overall response rates,"The overall response rates were 75% in the NRF, 67% in the SRI, and 56% in the ESRD groups.",Pharmacokinetics and Safety of Elotuzumab Combined With Lenalidomide and Dexamethasone in Patients With Multiple Myeloma and Various Levels of Renal Impairment: Results of a Phase Ib Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26795075/),%,67,184708,DB01041,Thalidomide
,26795075,overall response rates,"The overall response rates were 75% in the NRF, 67% in the SRI, and 56% in the ESRD groups.",Pharmacokinetics and Safety of Elotuzumab Combined With Lenalidomide and Dexamethasone in Patients With Multiple Myeloma and Various Levels of Renal Impairment: Results of a Phase Ib Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26795075/),%,56,184709,DB01041,Thalidomide
,32444867,progression-free survival (PFS),"Patients received standard doses of Pd. Median progression-free survival (PFS) for patients with RI was 9.5 months with Isa-Pd (n = 55) and 3.7 months with Pd (n = 49; hazard ratio [HR] 0.50; 95% confidence interval [CI], 0.30-0.85).",Isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients with renal impairment: ICARIA-MM subgroup analysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32444867/),month,9.5,190240,DB01041,Thalidomide
,32444867,progression-free survival (PFS),"Patients received standard doses of Pd. Median progression-free survival (PFS) for patients with RI was 9.5 months with Isa-Pd (n = 55) and 3.7 months with Pd (n = 49; hazard ratio [HR] 0.50; 95% confidence interval [CI], 0.30-0.85).",Isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients with renal impairment: ICARIA-MM subgroup analysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32444867/),month,3.7,190241,DB01041,Thalidomide
,32444867,PFS,"Without RI, median PFS was 12.7 months with Isa-Pd (n = 87) and 7.9 months with Pd (n = 96; HR 0.58; 95% CI, 0.38-0.88).",Isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients with renal impairment: ICARIA-MM subgroup analysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32444867/),month,12.7,190242,DB01041,Thalidomide
,32444867,PFS,"Without RI, median PFS was 12.7 months with Isa-Pd (n = 87) and 7.9 months with Pd (n = 96; HR 0.58; 95% CI, 0.38-0.88).",Isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients with renal impairment: ICARIA-MM subgroup analysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32444867/),month,7.9,190243,DB01041,Thalidomide
,32444867,overall response rate (ORR),The overall response rate (ORR) with and without RI was higher with Isa-Pd (56 and 68%) than Pd (25 and 43%).,Isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients with renal impairment: ICARIA-MM subgroup analysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32444867/),%,56,190244,DB01041,Thalidomide
,32444867,overall response rate (ORR),The overall response rate (ORR) with and without RI was higher with Isa-Pd (56 and 68%) than Pd (25 and 43%).,Isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients with renal impairment: ICARIA-MM subgroup analysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32444867/),%,68,190245,DB01041,Thalidomide
,32444867,overall response rate (ORR),The overall response rate (ORR) with and without RI was higher with Isa-Pd (56 and 68%) than Pd (25 and 43%).,Isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients with renal impairment: ICARIA-MM subgroup analysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32444867/),%,25,190246,DB01041,Thalidomide
,32444867,overall response rate (ORR),The overall response rate (ORR) with and without RI was higher with Isa-Pd (56 and 68%) than Pd (25 and 43%).,Isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients with renal impairment: ICARIA-MM subgroup analysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32444867/),%,43,190247,DB01041,Thalidomide
,32444867,Complete renal response rates,"Complete renal response rates were 71.9% (23/32) with Isa-Pd and 38.1% (8/21) with Pd; these lasted ≥60 days in 31.3% (10/32) and 19.0% (4/21) of patients, respectively.",Isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients with renal impairment: ICARIA-MM subgroup analysis. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32444867/),%,71.9,190248,DB01041,Thalidomide
,32444867,Complete renal response rates,"Complete renal response rates were 71.9% (23/32) with Isa-Pd and 38.1% (8/21) with Pd; these lasted ≥60 days in 31.3% (10/32) and 19.0% (4/21) of patients, respectively.",Isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients with renal impairment: ICARIA-MM subgroup analysis. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32444867/),%,38.1,190249,DB01041,Thalidomide
,32444867,Complete renal response rates,"Complete renal response rates were 71.9% (23/32) with Isa-Pd and 38.1% (8/21) with Pd; these lasted ≥60 days in 31.3% (10/32) and 19.0% (4/21) of patients, respectively.",Isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients with renal impairment: ICARIA-MM subgroup analysis. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32444867/),%,19,190250,DB01041,Thalidomide
,21825263,MTD,"The MTD of this combination regimen was 25 mg lenalidomide with 15 mg CCI-779, with toxicities of fatigue, neutropenia, and electrolyte wasting.",Phase I trial of lenalidomide and CCI-779 in patients with relapsed multiple myeloma: evidence for lenalidomide-CCI-779 interaction via P-glycoprotein. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21825263/),mg,25,191723,DB01041,Thalidomide
,17954615,t((1/2)),"As renal impairment progressed to moderate, severe, or end-stage renal disease, total and renal lenalidomide clearance decreased drastically, area under the concentration-time curve increased by approximately 185% to 420%, and t((1/2)) was prolonged by approximately 6 to 12 hours.",Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17954615/),h,6,193487,DB01041,Thalidomide
,16840727,Overall response rate,"Overall response rate (complete, partial, or minor) to lenalidomide alone was 25% (24% for once-daily and 29% for twice-daily lenalidomide).",A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16840727/),%,25,194061,DB01041,Thalidomide
,16840727,Overall response rate,"Overall response rate (complete, partial, or minor) to lenalidomide alone was 25% (24% for once-daily and 29% for twice-daily lenalidomide).",A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16840727/),%,24,194062,DB01041,Thalidomide
,16840727,Overall response rate,"Overall response rate (complete, partial, or minor) to lenalidomide alone was 25% (24% for once-daily and 29% for twice-daily lenalidomide).",A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16840727/),%,29,194063,DB01041,Thalidomide
,16840727,overall survival,"Median overall survival in 30-mg once-daily and twice-daily groups was 28 and 27 months, respectively.",A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16840727/),month,28,194064,DB01041,Thalidomide
,16840727,overall survival,"Median overall survival in 30-mg once-daily and twice-daily groups was 28 and 27 months, respectively.",A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16840727/),month,27,194065,DB01041,Thalidomide
,16840727,progression-free survival,Median progression-free survival was 7.7 months on once-daily versus 3.9 months on twice-daily lenalidomide (P = .2).,A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16840727/),month,7.7,194066,DB01041,Thalidomide
,16840727,progression-free survival,Median progression-free survival was 7.7 months on once-daily versus 3.9 months on twice-daily lenalidomide (P = .2).,A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16840727/),month,3.9,194067,DB01041,Thalidomide
,16840727,Time to first occurrence,"Time to first occurrence of clinically significant grade 3/4 myelosuppression was shorter in the twice-daily group (1.8 vs 5.5 months, P = .05).",A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16840727/),month,1.8,194068,DB01041,Thalidomide
,16840727,Time to first occurrence,"Time to first occurrence of clinically significant grade 3/4 myelosuppression was shorter in the twice-daily group (1.8 vs 5.5 months, P = .05).",A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16840727/),month,5.5,194069,DB01041,Thalidomide
,10579147,terminal half-life,"The terminal rate constant for the Tortuga formulation was significantly less, giving rise to a terminal half-life of 15 hours compared to about 5 to 6 hours for the Celgene formulations.",Single-dose oral pharmacokinetics of three formulations of thalidomide in healthy male volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10579147/),h,15,195597,DB01041,Thalidomide
,10579147,terminal half-life,"The terminal rate constant for the Tortuga formulation was significantly less, giving rise to a terminal half-life of 15 hours compared to about 5 to 6 hours for the Celgene formulations.",Single-dose oral pharmacokinetics of three formulations of thalidomide in healthy male volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10579147/),h,5 to 6,195598,DB01041,Thalidomide
,15651096,flow rate,"Thalidomide and dialysates were separated using a Zorbax ODS C(18) column and a mobile phase comprising acetonitrile-methanol-0.1 mm 1-octanesulufonic acid (32:3:65, v/v/v, pH 5.3) at flow rate of 1 mL min(-1).","Concurrent determination of thalidomide in rat blood, brain and bile using multiple microdialysis coupled to liquid chromatography. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15651096/),[ml] / [min],1,195927,DB01041,Thalidomide
,15651096,in vivo recoveries,"The average in vivo recoveries were 0.31+/- 0.02,0.046+/- 0.004 and 0.57+/- 0.02 (n=6), respective to the dialysates of blood, brain and bile, with thalidomide at concentrations 2, 5 and 10 microg mL(-1).","Concurrent determination of thalidomide in rat blood, brain and bile using multiple microdialysis coupled to liquid chromatography. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15651096/),,0.31,195928,DB01041,Thalidomide
,15651096,in vivo recoveries,"The average in vivo recoveries were 0.31+/- 0.02,0.046+/- 0.004 and 0.57+/- 0.02 (n=6), respective to the dialysates of blood, brain and bile, with thalidomide at concentrations 2, 5 and 10 microg mL(-1).","Concurrent determination of thalidomide in rat blood, brain and bile using multiple microdialysis coupled to liquid chromatography. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15651096/),,0.046,195929,DB01041,Thalidomide
,15651096,in vivo recoveries,"The average in vivo recoveries were 0.31+/- 0.02,0.046+/- 0.004 and 0.57+/- 0.02 (n=6), respective to the dialysates of blood, brain and bile, with thalidomide at concentrations 2, 5 and 10 microg mL(-1).","Concurrent determination of thalidomide in rat blood, brain and bile using multiple microdialysis coupled to liquid chromatography. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15651096/),,0.57,195930,DB01041,Thalidomide
,26956578,flow rate,"Separation of lenalidomide was performed on an Xterra RP C18 (250 mm length × 4.6 mm i.d., 5 µm) using a mobile phase consisting of phosphate buffer/acetonitrile (85:15, v/v, pH 3.2) at a flow rate of 0.5 mL · min-1 The samples were monitored at a wavelength of 311 nm.",A Wide Linearity Range Method for the Determination of Lenalidomide in Plasma by High-Performance Liquid Chromatography: Application to Pharmacokinetic Studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26956578/),[ml] / [min],0.5,201465,DB01041,Thalidomide
,26956578,limits of,"A linear relationship with good correlation coefficient (r = 0.997, n = 9) was found between the peak area and lenalidomide concentrations in the range of 100 to 950 ng · mL-1 The limits of detection and quantitation were 28 and 100 ng · mL-1, respectively.",A Wide Linearity Range Method for the Determination of Lenalidomide in Plasma by High-Performance Liquid Chromatography: Application to Pharmacokinetic Studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26956578/),[ng] / [ml],28,201466,DB01041,Thalidomide
,27848182,durations,Maximum (median) durations of study therapy were 36.6 (35.2) months in Cohort 1 and 28.3 (9.2) months in Cohort 2.,Elotuzumab with lenalidomide and dexamethasone for Japanese patients with relapsed/refractory multiple myeloma: phase 1 study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27848182/),month,36.6,201723,DB01041,Thalidomide
,27848182,durations,Maximum (median) durations of study therapy were 36.6 (35.2) months in Cohort 1 and 28.3 (9.2) months in Cohort 2.,Elotuzumab with lenalidomide and dexamethasone for Japanese patients with relapsed/refractory multiple myeloma: phase 1 study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27848182/),month,28.3,201724,DB01041,Thalidomide
,27848182,Overall response,"Overall response was 83% (n = 5): one complete response, three very good partial responses, one partial response.",Elotuzumab with lenalidomide and dexamethasone for Japanese patients with relapsed/refractory multiple myeloma: phase 1 study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27848182/),%,83,201725,DB01041,Thalidomide
,15522712,flow rate,"Separation of the compounds of interest was achieved on a column packed with Waters C18 Nova-Pak material (4 microm particle size; 300 mm x 3.9 mm internal diameter) using acetonitrile, de-ionized water, and glacial acetic acid in ratios of 20:80:0.1 (v/v/v) (pH 3.5) delivered at an isocratic flow rate of 1.00 ml/min.","Determination of CC-5013, an analogue of thalidomide, in human plasma by liquid chromatography-mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15522712/),[ml] / [min],1.00,207890,DB01041,Thalidomide
,2501333,recovery,The recovery of the extraction procedures was 65-80%.,"Determination of the thalidomide analogues 2-(2,6-dioxopiperidine-3-yl)phthalimidine (EM 12), 2-(2,6-dioxopiperidine-4-yl)phthalimidine (EM 16) and their metabolites in biological samples. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2501333/),%,65-80,209880,DB01041,Thalidomide
,15514381,area under the concentration-time curve,Carboplatin was administered as a single intravenous dose once every 21 days at a target area under the concentration-time curve of 6 mg/mL.min.,Phase I and pharmacokinetic study of thalidomide with carboplatin in children with cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15514381/),[mg] / [min·ml],6,215006,DB01041,Thalidomide
,15514381,apparent clearance,Thalidomide's apparent clearance was 55 +/- 16 mL/min/m(2) and the terminal half-life was 5.9 +/- 2.8 hours.,Phase I and pharmacokinetic study of thalidomide with carboplatin in children with cancer. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15514381/),[min·ml] / [m(2],55,215007,DB01041,Thalidomide
,15514381,terminal half-life,Thalidomide's apparent clearance was 55 +/- 16 mL/min/m(2) and the terminal half-life was 5.9 +/- 2.8 hours.,Phase I and pharmacokinetic study of thalidomide with carboplatin in children with cancer. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15514381/),h,5.9,215008,DB01041,Thalidomide
,27085994,progression-free survival,"The median progression-free survival and overall survival were 2.8 and 5.5 months, respectively.",Phase I clinical trial of lenalidomide in combination with bevacizumab in patients with advanced cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27085994/),month,2.8,215210,DB01041,Thalidomide
,27085994,overall survival,"The median progression-free survival and overall survival were 2.8 and 5.5 months, respectively.",Phase I clinical trial of lenalidomide in combination with bevacizumab in patients with advanced cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27085994/),month,5.5,215211,DB01041,Thalidomide
,17077542,apparent volume of distribution (Vd/F),"The average apparent volume of distribution (Vd/F), apparent total clearance (CL/F) and area under the plasma concentration-time curve from 0 to infinity (AUC0-infinity), which were 45.3 l, 5.5 l/h and 21.7 microg.h/ml, respectively, with smaller Vd/F and CL/F and larger AUC0-infinity than in Caucasian populations.",The pharmacokinetics of low-dose thalidomide in Japanese patients with refractory multiple myeloma. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17077542/),l,45.3,216625,DB01041,Thalidomide
,17077542,apparent total clearance (CL/F),"The average apparent volume of distribution (Vd/F), apparent total clearance (CL/F) and area under the plasma concentration-time curve from 0 to infinity (AUC0-infinity), which were 45.3 l, 5.5 l/h and 21.7 microg.h/ml, respectively, with smaller Vd/F and CL/F and larger AUC0-infinity than in Caucasian populations.",The pharmacokinetics of low-dose thalidomide in Japanese patients with refractory multiple myeloma. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17077542/),[l] / [h],5.5,216626,DB01041,Thalidomide
,17077542,area under the plasma concentration-time curve from 0 to infinity (AUC0-infinity),"The average apparent volume of distribution (Vd/F), apparent total clearance (CL/F) and area under the plasma concentration-time curve from 0 to infinity (AUC0-infinity), which were 45.3 l, 5.5 l/h and 21.7 microg.h/ml, respectively, with smaller Vd/F and CL/F and larger AUC0-infinity than in Caucasian populations.",The pharmacokinetics of low-dose thalidomide in Japanese patients with refractory multiple myeloma. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17077542/),[h·μg] / [ml],21.7,216627,DB01041,Thalidomide
,30272138,flow rate,"Chromatographic analysis was achieved firstly by HPLC method on C18 column (150 × 4.6 mm2 i.d., 5 μm) and a mobile phase composed of ethanol:water (containing 0.1% acetic acid) (70:30, v/v) at the flow rate of 0.6 mL min-1.",Simultaneous Determination of Thalidomide and Dexamethasone in Rat Plasma by Validated HPLC and HPTLC With Pharmacokinetic Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30272138/),[ml] / [min],0.6,217803,DB01041,Thalidomide
,28483761,overall response rate (ORR),"In the efficacy-evaluable population, the overall response rate (ORR) was 56% (29/52) and was similar between the 10 mg/kg Q2W and 10 and 20 mg/kg QW/Q2W cohorts.",A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myeloma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28483761/),%,56,219599,DB01041,Thalidomide
,28483761,progression-free survival,Overall median progression-free survival was 8.5 months.,A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myeloma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28483761/),month,8.5,219600,DB01041,Thalidomide
,19399582,overall response rate,"The overall response rate was 35.3% (12/34), including partial response of 14.7% (5/34) and minimal response of 20.6% (7/34).",Phase II and pharmacokinetic study of thalidomide in Japanese patients with relapsed/refractory multiple myeloma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19399582/),%,35.3,220355,DB01041,Thalidomide
,19399582,C (max),"At a single oral dose of thalidomide (100 mg), the C (max) was 1.68 +/- 0.41 microg/ml, T (max) was 4.54 +/- 1.71 h, T (1/2) was 4.86 +/- 0.44 h, and AUC was 15.87 +/- 3.05 microg h/ml.",Phase II and pharmacokinetic study of thalidomide in Japanese patients with relapsed/refractory multiple myeloma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19399582/),[μg] / [ml],1.68,220356,DB01041,Thalidomide
,19399582,T (max),"At a single oral dose of thalidomide (100 mg), the C (max) was 1.68 +/- 0.41 microg/ml, T (max) was 4.54 +/- 1.71 h, T (1/2) was 4.86 +/- 0.44 h, and AUC was 15.87 +/- 3.05 microg h/ml.",Phase II and pharmacokinetic study of thalidomide in Japanese patients with relapsed/refractory multiple myeloma. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19399582/),h,4.54,220357,DB01041,Thalidomide
,19399582,T (1/2),"At a single oral dose of thalidomide (100 mg), the C (max) was 1.68 +/- 0.41 microg/ml, T (max) was 4.54 +/- 1.71 h, T (1/2) was 4.86 +/- 0.44 h, and AUC was 15.87 +/- 3.05 microg h/ml.",Phase II and pharmacokinetic study of thalidomide in Japanese patients with relapsed/refractory multiple myeloma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19399582/),h,4.86,220358,DB01041,Thalidomide
,19399582,AUC,"At a single oral dose of thalidomide (100 mg), the C (max) was 1.68 +/- 0.41 microg/ml, T (max) was 4.54 +/- 1.71 h, T (1/2) was 4.86 +/- 0.44 h, and AUC was 15.87 +/- 3.05 microg h/ml.",Phase II and pharmacokinetic study of thalidomide in Japanese patients with relapsed/refractory multiple myeloma. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19399582/),[h·μg] / [ml],15.87,220359,DB01041,Thalidomide
,27165568,total run time,"The total run time was 3.0 min, and the elution of apremilast was at 1.27 min.",Determination of Apremilast in Rat Plasma by UPLC-MS-MS and Its Application to a Pharmacokinetic Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27165568/),min,3.0,220752,DB01041,Thalidomide
,27165568,elution,"The total run time was 3.0 min, and the elution of apremilast was at 1.27 min.",Determination of Apremilast in Rat Plasma by UPLC-MS-MS and Its Application to a Pharmacokinetic Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27165568/),min,1.27,220753,DB01041,Thalidomide
,27165568,recovery,The mean recovery of apremilast in plasma was in the range of 83.2-87.5%.,Determination of Apremilast in Rat Plasma by UPLC-MS-MS and Its Application to a Pharmacokinetic Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27165568/),%,83.2-87.5,220754,DB01041,Thalidomide
,15059136,Rate of absorption,"Rate of absorption, rate of elimination, volume of distribution, clearance and elimination half-life were calculated to be 0.200/h, 0.140/h, 0.886 l/kg, 0.126 l/h/kg and 4.98 h respectively.",Early response predicts thalidomide efficiency in patients with advanced multiple myeloma. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15059136/),1/[h],0.200,229630,DB01041,Thalidomide
,15059136,volume of distribution,"Rate of absorption, rate of elimination, volume of distribution, clearance and elimination half-life were calculated to be 0.200/h, 0.140/h, 0.886 l/kg, 0.126 l/h/kg and 4.98 h respectively.",Early response predicts thalidomide efficiency in patients with advanced multiple myeloma. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15059136/),1/[h],0.140,229631,DB01041,Thalidomide
,15059136,clearance,"Rate of absorption, rate of elimination, volume of distribution, clearance and elimination half-life were calculated to be 0.200/h, 0.140/h, 0.886 l/kg, 0.126 l/h/kg and 4.98 h respectively.",Early response predicts thalidomide efficiency in patients with advanced multiple myeloma. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15059136/),1/[h],0.140,229632,DB01041,Thalidomide
,15059136,elimination half-life,"Rate of absorption, rate of elimination, volume of distribution, clearance and elimination half-life were calculated to be 0.200/h, 0.140/h, 0.886 l/kg, 0.126 l/h/kg and 4.98 h respectively.",Early response predicts thalidomide efficiency in patients with advanced multiple myeloma. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15059136/),h,4.98,229633,DB01041,Thalidomide
,11038436,absorption lag time,"The high-fat meal resulted in a 0.5-1.5 h absorption lag time, an increased mean C(max), a decreased mean AUC and a delay in mean T(max).",Effect of a high-fat meal on thalidomide pharmacokinetics and the relative bioavailability of oral formulations in healthy men and women. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11038436/),h,0.5-1.5,230041,DB01041,Thalidomide
,11038436,C(max) concentrations,"Mean C(max) concentrations were 1.99+/-0.41 microg/mL (range 1.28-2.76) within 4.00+/-1.13 h (2-5) for the Celgene formulation fasted, 2.17+/-0.51 microg/mL (1.43-3.01) within 6.08+/-2.33 h (3-12) for the Celgene formulation with food, and 1. 05+/-0.31 microg/mL (0.62-1.65) within 6.23+/-1.88 h (5-10) for the Serral formulation fasted.",Effect of a high-fat meal on thalidomide pharmacokinetics and the relative bioavailability of oral formulations in healthy men and women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11038436/),[μg] / [ml],1.99,230042,DB01041,Thalidomide
,11038436,C(max) concentrations,"Mean C(max) concentrations were 1.99+/-0.41 microg/mL (range 1.28-2.76) within 4.00+/-1.13 h (2-5) for the Celgene formulation fasted, 2.17+/-0.51 microg/mL (1.43-3.01) within 6.08+/-2.33 h (3-12) for the Celgene formulation with food, and 1. 05+/-0.31 microg/mL (0.62-1.65) within 6.23+/-1.88 h (5-10) for the Serral formulation fasted.",Effect of a high-fat meal on thalidomide pharmacokinetics and the relative bioavailability of oral formulations in healthy men and women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11038436/),[μg] / [ml],2.17,230043,DB01041,Thalidomide
,11038436,C(max) concentrations,"Mean C(max) concentrations were 1.99+/-0.41 microg/mL (range 1.28-2.76) within 4.00+/-1.13 h (2-5) for the Celgene formulation fasted, 2.17+/-0.51 microg/mL (1.43-3.01) within 6.08+/-2.33 h (3-12) for the Celgene formulation with food, and 1. 05+/-0.31 microg/mL (0.62-1.65) within 6.23+/-1.88 h (5-10) for the Serral formulation fasted.",Effect of a high-fat meal on thalidomide pharmacokinetics and the relative bioavailability of oral formulations in healthy men and women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11038436/),[μg] / [ml],1. 05,230044,DB01041,Thalidomide
,11038436,terminal half-lives,Mean terminal half-lives were 13.50+/-6.,Effect of a high-fat meal on thalidomide pharmacokinetics and the relative bioavailability of oral formulations in healthy men and women. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11038436/),,13.50,230045,DB01041,Thalidomide
,11038436,ratios,"Celgene's formulation exhibited slightly greater bioavailability than Serral's formulation, with mean ratios of 122% and 110% for Ln-transformed AUC(0-t) and AUC(0-infinity), respectively.",Effect of a high-fat meal on thalidomide pharmacokinetics and the relative bioavailability of oral formulations in healthy men and women. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11038436/),,122,230046,DB01041,Thalidomide
,11038436,ratios,"Celgene's formulation exhibited slightly greater bioavailability than Serral's formulation, with mean ratios of 122% and 110% for Ln-transformed AUC(0-t) and AUC(0-infinity), respectively.",Effect of a high-fat meal on thalidomide pharmacokinetics and the relative bioavailability of oral formulations in healthy men and women. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11038436/),,110,230047,DB01041,Thalidomide
,24295177,limit of detection,The assay limit of detection was 0.05 ng/mL and the effective working range at relative standard deviations (RSD) of ≤5% was 0.1-20 ng/mL.,A highly sensitive polyclonal antibody-based ELISA for therapeutic monitoring and pharmacokinetic studies of lenalidomide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24295177/),[ng] / [ml],0.05,231880,DB01041,Thalidomide
,24295177,Analytical recovery,Analytical recovery of LND from spiked plasma was 100.98 ± 3.05.,A highly sensitive polyclonal antibody-based ELISA for therapeutic monitoring and pharmacokinetic studies of lenalidomide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24295177/),,100.98,231881,DB01041,Thalidomide
,20559759,overall response rate,"In the combination cohort, the overall response rate (> or =PR) was 100%.",Lenalidomide plus dexamethasone treatment in Japanese patients with relapsed/refractory multiple myeloma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20559759/),%,100,233350,DB01041,Thalidomide
,9874712,oral clearance,"After single dosing, the oral clearance and apparent volume of distribution for the low-dose regimen (n = 13) were 7.41 +/- 2.05 L/h and 66.93 +/- 34.27 L, respectively, whereas for the high-dose regimen (n = 11), these values were 7.21 +/- 2.89 L/h and 165.81 +/- 84.18 L, respectively.",Pharmacokinetics of thalidomide in an elderly prostate cancer population. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9874712/),[l] / [h],7.41,238353,DB01041,Thalidomide
,9874712,oral clearance,"After single dosing, the oral clearance and apparent volume of distribution for the low-dose regimen (n = 13) were 7.41 +/- 2.05 L/h and 66.93 +/- 34.27 L, respectively, whereas for the high-dose regimen (n = 11), these values were 7.21 +/- 2.89 L/h and 165.81 +/- 84.18 L, respectively.",Pharmacokinetics of thalidomide in an elderly prostate cancer population. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9874712/),[l] / [h],7.21,238354,DB01041,Thalidomide
,9874712,apparent volume of distribution,"After single dosing, the oral clearance and apparent volume of distribution for the low-dose regimen (n = 13) were 7.41 +/- 2.05 L/h and 66.93 +/- 34.27 L, respectively, whereas for the high-dose regimen (n = 11), these values were 7.21 +/- 2.89 L/h and 165.81 +/- 84.18 L, respectively.",Pharmacokinetics of thalidomide in an elderly prostate cancer population. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9874712/),l,66.93,238355,DB01041,Thalidomide
,9874712,apparent volume of distribution,"After single dosing, the oral clearance and apparent volume of distribution for the low-dose regimen (n = 13) were 7.41 +/- 2.05 L/h and 66.93 +/- 34.27 L, respectively, whereas for the high-dose regimen (n = 11), these values were 7.21 +/- 2.89 L/h and 165.81 +/- 84.18 L, respectively.",Pharmacokinetics of thalidomide in an elderly prostate cancer population. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9874712/),l,165.81,238356,DB01041,Thalidomide
,9874712,elimination half-lives,"The elimination half-lives for the low and high dose were 6.52 +/- 3.81 and 18.25 +/- 14.08 h, respectively.",Pharmacokinetics of thalidomide in an elderly prostate cancer population. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9874712/),h,6.52,238357,DB01041,Thalidomide
,9874712,elimination half-lives,"The elimination half-lives for the low and high dose were 6.52 +/- 3.81 and 18.25 +/- 14.08 h, respectively.",Pharmacokinetics of thalidomide in an elderly prostate cancer population. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9874712/),h,18.25,238358,DB01041,Thalidomide
,9874712,oral clearance,"After the multiple dosing of thalidomide, the oral clearance and apparent volume of distribution for the low-dose group (n = 10) were 6.35 +/- 1.64 L/h and 64.63 +/- 23.20 L, respectively, whereas for the high-dose group (n = 11), these values were 7.73 +/- 2.27 L/h and 167.85 +/- 82.08 L, respectively.",Pharmacokinetics of thalidomide in an elderly prostate cancer population. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9874712/),[l] / [h],6.35,238359,DB01041,Thalidomide
,9874712,oral clearance,"After the multiple dosing of thalidomide, the oral clearance and apparent volume of distribution for the low-dose group (n = 10) were 6.35 +/- 1.64 L/h and 64.63 +/- 23.20 L, respectively, whereas for the high-dose group (n = 11), these values were 7.73 +/- 2.27 L/h and 167.85 +/- 82.08 L, respectively.",Pharmacokinetics of thalidomide in an elderly prostate cancer population. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9874712/),[l] / [h],7.73,238360,DB01041,Thalidomide
,9874712,apparent volume of distribution,"After the multiple dosing of thalidomide, the oral clearance and apparent volume of distribution for the low-dose group (n = 10) were 6.35 +/- 1.64 L/h and 64.63 +/- 23.20 L, respectively, whereas for the high-dose group (n = 11), these values were 7.73 +/- 2.27 L/h and 167.85 +/- 82.08 L, respectively.",Pharmacokinetics of thalidomide in an elderly prostate cancer population. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9874712/),l,64.63,238361,DB01041,Thalidomide
,9874712,apparent volume of distribution,"After the multiple dosing of thalidomide, the oral clearance and apparent volume of distribution for the low-dose group (n = 10) were 6.35 +/- 1.64 L/h and 64.63 +/- 23.20 L, respectively, whereas for the high-dose group (n = 11), these values were 7.73 +/- 2.27 L/h and 167.85 +/- 82.08 L, respectively.",Pharmacokinetics of thalidomide in an elderly prostate cancer population. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9874712/),l,167.85,238362,DB01041,Thalidomide
,9874712,elimination half-lives,"The elimination half-lives for the low and high dose were 7.08 +/- 1.87 and 16.19 +/- 9.57 h, respectively.",Pharmacokinetics of thalidomide in an elderly prostate cancer population. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9874712/),h,7.08,238363,DB01041,Thalidomide
,9874712,elimination half-lives,"The elimination half-lives for the low and high dose were 7.08 +/- 1.87 and 16.19 +/- 9.57 h, respectively.",Pharmacokinetics of thalidomide in an elderly prostate cancer population. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9874712/),h,16.19,238364,DB01041,Thalidomide
,29076150,overall response rate,"The overall response rate and clinical benefit rate was 53% (19/36) and 64% (23/36), respectively.","A phase 1 clinical trial evaluating marizomib, pomalidomide and low-dose dexamethasone in relapsed and refractory multiple myeloma (NPI-0052-107): final study results. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29076150/),%,53,241002,DB01041,Thalidomide
,29076150,clinical benefit rate,"The overall response rate and clinical benefit rate was 53% (19/36) and 64% (23/36), respectively.","A phase 1 clinical trial evaluating marizomib, pomalidomide and low-dose dexamethasone in relapsed and refractory multiple myeloma (NPI-0052-107): final study results. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29076150/),%,64,241003,DB01041,Thalidomide
,22037879,T (max),"Metabolite profiling and quantitation were accomplished using liquid chromatography with mass spectrometric and radiochemical detection. [(14)C]-Lenalidomide was rapidly absorbed (T (max) 0.77-1.0 h), and the levels declined with a terminal half-life of approximately 3 h, with similar profiles for total blood and plasma radioactivity as well as plasma lenalidomide.","Pharmacokinetics, metabolism and excretion of [(14)C]-lenalidomide following oral administration in healthy male subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22037879/),h,0.77-1.0,241572,DB01041,Thalidomide
,22037879,terminal half-life,"Metabolite profiling and quantitation were accomplished using liquid chromatography with mass spectrometric and radiochemical detection. [(14)C]-Lenalidomide was rapidly absorbed (T (max) 0.77-1.0 h), and the levels declined with a terminal half-life of approximately 3 h, with similar profiles for total blood and plasma radioactivity as well as plasma lenalidomide.","Pharmacokinetics, metabolism and excretion of [(14)C]-lenalidomide following oral administration in healthy male subjects. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22037879/),h,3,241573,DB01041,Thalidomide
,15936253,total body clearance (CL),"Accordingly, the value of total body clearance (CL) of CPT-11 lactone was significantly lower in combination group compared to the control (1.329 versus 1.837 L/h/kg, P = 0.0002).",Simultaneous determination of the lactone and carboxylate forms of irinotecan (CPT-11) and its active metabolite SN-38 by high-performance liquid chromatography: application to plasma pharmacokinetic studies in the rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15936253/),[l] / [h·kg],1.329,241595,DB01041,Thalidomide
,15936253,total body clearance (CL),"Accordingly, the value of total body clearance (CL) of CPT-11 lactone was significantly lower in combination group compared to the control (1.329 versus 1.837 L/h/kg, P = 0.0002).",Simultaneous determination of the lactone and carboxylate forms of irinotecan (CPT-11) and its active metabolite SN-38 by high-performance liquid chromatography: application to plasma pharmacokinetic studies in the rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15936253/),[l] / [h·kg],1.837,241596,DB01041,Thalidomide
,24920586,maximum tolerated dose,"The maximum tolerated dose was 2.0 mg/m(2), which 40 patients received in 4 expansion cohorts.","Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24920586/),[mg] / [m(2],2.0,242784,DB01041,Thalidomide
,24920586,terminal half-life,The terminal half-life of ixazomib was 3.3 to 7.4 days; plasma exposure increased proportionally with dose (0.48-2.23 mg/m(2)).,"Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24920586/),d,3.3 to 7.4,242785,DB01041,Thalidomide
,23782711,disease control rate,"In the efficacy population (n = 187), the disease control rate (at least stable disease) was 94.7%, and the overall response rate (at least partial response) was 47.6%.","A multicenter, open-label, phase 2 study of lenalidomide plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma: the MM-021 trial. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23782711/),%,94.,250339,DB01041,Thalidomide
,23782711,overall response rate,"In the efficacy population (n = 187), the disease control rate (at least stable disease) was 94.7%, and the overall response rate (at least partial response) was 47.6%.","A multicenter, open-label, phase 2 study of lenalidomide plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma: the MM-021 trial. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23782711/),%,47.6,250340,DB01041,Thalidomide
,23782711,response duration,"After a median study follow-up of 15.2 months, the median response duration was 8.8 months (range, 0.4-18.8 months) and median progression-free survival was 8.3 months (95% CI 6.5-9.8).","A multicenter, open-label, phase 2 study of lenalidomide plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma: the MM-021 trial. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23782711/),month,8.8,250341,DB01041,Thalidomide
,23782711,progression-free survival,"After a median study follow-up of 15.2 months, the median response duration was 8.8 months (range, 0.4-18.8 months) and median progression-free survival was 8.3 months (95% CI 6.5-9.8).","A multicenter, open-label, phase 2 study of lenalidomide plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma: the MM-021 trial. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23782711/),month,8.3,250342,DB01041,Thalidomide
,31518681,plasma ratios,"Predicted foetal exposure to thalidomide was higher than efavirenz, with median (range) foetal-to-maternal plasma ratios of 4.55 (3.06-9.57) for 400 mg thalidomide versus 0.89 (0.73-1.05) for 400 mg efavirenz at third trimester.",Using mechanistic physiologically-based pharmacokinetic models to assess prenatal drug exposure: Thalidomide versus efavirenz as case studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31518681/),,4.55,254327,DB01041,Thalidomide
,31518681,plasma ratios,"Predicted foetal exposure to thalidomide was higher than efavirenz, with median (range) foetal-to-maternal plasma ratios of 4.55 (3.06-9.57) for 400 mg thalidomide versus 0.89 (0.73-1.05) for 400 mg efavirenz at third trimester.",Using mechanistic physiologically-based pharmacokinetic models to assess prenatal drug exposure: Thalidomide versus efavirenz as case studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31518681/),,0.,254328,DB01041,Thalidomide
,7702998,rate constants,"Mean rate constants of chiral inversion of (+)-(R)-thalidomide and (-)-(S)-thalidomide in blood at 37 degrees C were 0.30 and 0.31 h-1, respectively.","Stereospecific determination, chiral inversion in vitro and pharmacokinetics in humans of the enantiomers of thalidomide. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7702998/),1/[h],0.30,261445,DB01041,Thalidomide
,7702998,rate constants,"Mean rate constants of chiral inversion of (+)-(R)-thalidomide and (-)-(S)-thalidomide in blood at 37 degrees C were 0.30 and 0.31 h-1, respectively.","Stereospecific determination, chiral inversion in vitro and pharmacokinetics in humans of the enantiomers of thalidomide. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7702998/),1/[h],0.31,261446,DB01041,Thalidomide
,7702998,Rate constants of degradation,Rate constants of degradation were 0.17 and 0.18 h-1.,"Stereospecific determination, chiral inversion in vitro and pharmacokinetics in humans of the enantiomers of thalidomide. ",Kdeg-Q12,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7702998/),1/[h],0.17,261447,DB01041,Thalidomide
,7702998,Rate constants of degradation,Rate constants of degradation were 0.17 and 0.18 h-1.,"Stereospecific determination, chiral inversion in vitro and pharmacokinetics in humans of the enantiomers of thalidomide. ",Kdeg-Q12,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7702998/),1/[h],0.18,261448,DB01041,Thalidomide
,7702998,rate constants,"Mean rate constants for in vivo inversion were 0.17 h-1 (R to S) and 0.12 h-1 (S to R) and for elimination 0.079 h-1 (R) and 0.24 h-1 (S), i.e., a considerably faster rate of elimination of the (-)-(S)-enantiomer.","Stereospecific determination, chiral inversion in vitro and pharmacokinetics in humans of the enantiomers of thalidomide. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7702998/),1/[h],0.17,261449,DB01041,Thalidomide
,7702998,rate constants,"Mean rate constants for in vivo inversion were 0.17 h-1 (R to S) and 0.12 h-1 (S to R) and for elimination 0.079 h-1 (R) and 0.24 h-1 (S), i.e., a considerably faster rate of elimination of the (-)-(S)-enantiomer.","Stereospecific determination, chiral inversion in vitro and pharmacokinetics in humans of the enantiomers of thalidomide. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7702998/),1/[h],0.12,261450,DB01041,Thalidomide
,7702998,rate constants,"Mean rate constants for in vivo inversion were 0.17 h-1 (R to S) and 0.12 h-1 (S to R) and for elimination 0.079 h-1 (R) and 0.24 h-1 (S), i.e., a considerably faster rate of elimination of the (-)-(S)-enantiomer.","Stereospecific determination, chiral inversion in vitro and pharmacokinetics in humans of the enantiomers of thalidomide. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7702998/),1/[h],0.079,261451,DB01041,Thalidomide
,7702998,rate constants,"Mean rate constants for in vivo inversion were 0.17 h-1 (R to S) and 0.12 h-1 (S to R) and for elimination 0.079 h-1 (R) and 0.24 h-1 (S), i.e., a considerably faster rate of elimination of the (-)-(S)-enantiomer.","Stereospecific determination, chiral inversion in vitro and pharmacokinetics in humans of the enantiomers of thalidomide. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7702998/),1/[h],0.24,261452,DB01041,Thalidomide
,7702998,elimination,"Mean rate constants for in vivo inversion were 0.17 h-1 (R to S) and 0.12 h-1 (S to R) and for elimination 0.079 h-1 (R) and 0.24 h-1 (S), i.e., a considerably faster rate of elimination of the (-)-(S)-enantiomer.","Stereospecific determination, chiral inversion in vitro and pharmacokinetics in humans of the enantiomers of thalidomide. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7702998/),1/[h],0.079,261453,DB01041,Thalidomide
,7702998,elimination,"Mean rate constants for in vivo inversion were 0.17 h-1 (R to S) and 0.12 h-1 (S to R) and for elimination 0.079 h-1 (R) and 0.24 h-1 (S), i.e., a considerably faster rate of elimination of the (-)-(S)-enantiomer.","Stereospecific determination, chiral inversion in vitro and pharmacokinetics in humans of the enantiomers of thalidomide. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7702998/),1/[h],0.24,261454,DB01041,Thalidomide
,27286995,Overall response,"Overall response was 76 %, and safety profiles were similar across groups, with no exposure-dependent trend in efficacy or toxicity.","Pharmacokinetics, safety, and efficacy of lenalidomide plus dexamethasone in patients with multiple myeloma and renal impairment. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27286995/),%,76,261754,DB01041,Thalidomide
,27531679,overall response rate,"In part 2 (median follow-up of 15.6 months), overall response rate was 81%, with 8 stringent complete responses (25%), 3 complete responses (9%), and 9 very good partial responses (28%).","Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27531679/),%,81,263453,DB01041,Thalidomide
,22382316,areas under the curve (AUC),"The areas under the curve (AUC) of (R)-thalidomide were 3.42 and 5.33 μg·h/L, and those of (S)-thalidomide were 1.64 and 2.46 μg·h/L for hetEM and PM, respectively.",Influence of cytochrome P450 2C19 gene variations on pharmacokinetic parameters of thalidomide in Japanese patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22382316/),[h·μg] / [l],3.42,263599,DB01041,Thalidomide
,22382316,areas under the curve (AUC),"The areas under the curve (AUC) of (R)-thalidomide were 3.42 and 5.33 μg·h/L, and those of (S)-thalidomide were 1.64 and 2.46 μg·h/L for hetEM and PM, respectively.",Influence of cytochrome P450 2C19 gene variations on pharmacokinetic parameters of thalidomide in Japanese patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22382316/),[h·μg] / [l],5.33,263600,DB01041,Thalidomide
,22382316,areas under the curve (AUC),"The areas under the curve (AUC) of (R)-thalidomide were 3.42 and 5.33 μg·h/L, and those of (S)-thalidomide were 1.64 and 2.46 μg·h/L for hetEM and PM, respectively.",Influence of cytochrome P450 2C19 gene variations on pharmacokinetic parameters of thalidomide in Japanese patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22382316/),[h·μg] / [l],1.64,263601,DB01041,Thalidomide
,22382316,areas under the curve (AUC),"The areas under the curve (AUC) of (R)-thalidomide were 3.42 and 5.33 μg·h/L, and those of (S)-thalidomide were 1.64 and 2.46 μg·h/L for hetEM and PM, respectively.",Influence of cytochrome P450 2C19 gene variations on pharmacokinetic parameters of thalidomide in Japanese patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22382316/),[h·μg] / [l],2.46,263602,DB01041,Thalidomide
below,14738599,Clearance,"Clearance and volumes were slightly below 10 L h-1 and 1 L kg-1, respectively, in both patient groups.",Pharmacokinetics of thalidomide in patients with impaired renal function and while on and off dialysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14738599/),[l] / [h],10,264075,DB01041,Thalidomide
,14738599,volumes,"Clearance and volumes were slightly below 10 L h-1 and 1 L kg-1, respectively, in both patient groups.",Pharmacokinetics of thalidomide in patients with impaired renal function and while on and off dialysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14738599/),[l] / [kg],1,264076,DB01041,Thalidomide
,29926217,Cmax,"Subjects administered test lenalidomide and Revlimid® capsules in the fasting state had a Cmax of 564 ± 153 and 609 ± 121 ng/mL, respectively; an AUC0-t of 1660 ± 211 and 1660 ± 235 h ng/mL, respectively; and an AUC0-∞ of 1670 ± 210 and 1670 ± 237 h ng/mL, respectively.",Bioequivalence study of single-dose lenalidomide capsule vs. Revlimid® capsule in healthy Chinese males. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29926217/),[ng] / [ml],564,264204,DB01041,Thalidomide
,29926217,Cmax,"Subjects administered test lenalidomide and Revlimid® capsules in the fasting state had a Cmax of 564 ± 153 and 609 ± 121 ng/mL, respectively; an AUC0-t of 1660 ± 211 and 1660 ± 235 h ng/mL, respectively; and an AUC0-∞ of 1670 ± 210 and 1670 ± 237 h ng/mL, respectively.",Bioequivalence study of single-dose lenalidomide capsule vs. Revlimid® capsule in healthy Chinese males. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29926217/),[ng] / [ml],609,264205,DB01041,Thalidomide
,29926217,AUC0-t,"Subjects administered test lenalidomide and Revlimid® capsules in the fasting state had a Cmax of 564 ± 153 and 609 ± 121 ng/mL, respectively; an AUC0-t of 1660 ± 211 and 1660 ± 235 h ng/mL, respectively; and an AUC0-∞ of 1670 ± 210 and 1670 ± 237 h ng/mL, respectively.",Bioequivalence study of single-dose lenalidomide capsule vs. Revlimid® capsule in healthy Chinese males. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29926217/),[h·ng] / [ml],1660,264206,DB01041,Thalidomide
,29926217,AUC0-t,"Subjects administered test lenalidomide and Revlimid® capsules in the fasting state had a Cmax of 564 ± 153 and 609 ± 121 ng/mL, respectively; an AUC0-t of 1660 ± 211 and 1660 ± 235 h ng/mL, respectively; and an AUC0-∞ of 1670 ± 210 and 1670 ± 237 h ng/mL, respectively.",Bioequivalence study of single-dose lenalidomide capsule vs. Revlimid® capsule in healthy Chinese males. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29926217/),[h·ng] / [ml],1660,264207,DB01041,Thalidomide
,29926217,AUC0-∞,"Subjects administered test lenalidomide and Revlimid® capsules in the fasting state had a Cmax of 564 ± 153 and 609 ± 121 ng/mL, respectively; an AUC0-t of 1660 ± 211 and 1660 ± 235 h ng/mL, respectively; and an AUC0-∞ of 1670 ± 210 and 1670 ± 237 h ng/mL, respectively.",Bioequivalence study of single-dose lenalidomide capsule vs. Revlimid® capsule in healthy Chinese males. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29926217/),[h·ng] / [ml],1670,264208,DB01041,Thalidomide
,29926217,AUC0-∞,"Subjects administered test lenalidomide and Revlimid® capsules in the fasting state had a Cmax of 564 ± 153 and 609 ± 121 ng/mL, respectively; an AUC0-t of 1660 ± 211 and 1660 ± 235 h ng/mL, respectively; and an AUC0-∞ of 1670 ± 210 and 1670 ± 237 h ng/mL, respectively.",Bioequivalence study of single-dose lenalidomide capsule vs. Revlimid® capsule in healthy Chinese males. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29926217/),[h·ng] / [ml],1670,264209,DB01041,Thalidomide
,29926217,Cmax,"In the fed state, the subjects had a Cmax of 389 ± 105 and 383 ± 101 ng/mL, respectively; an AUC0-t of 1770 ± 314 and 1740 ± 360 h ng/mL, respectively; and an AUC0-∞ of 1800 ± 316 and 1760 ± 362 h ng/mL, respectively.",Bioequivalence study of single-dose lenalidomide capsule vs. Revlimid® capsule in healthy Chinese males. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29926217/),[ng] / [ml],389,264210,DB01041,Thalidomide
,29926217,Cmax,"In the fed state, the subjects had a Cmax of 389 ± 105 and 383 ± 101 ng/mL, respectively; an AUC0-t of 1770 ± 314 and 1740 ± 360 h ng/mL, respectively; and an AUC0-∞ of 1800 ± 316 and 1760 ± 362 h ng/mL, respectively.",Bioequivalence study of single-dose lenalidomide capsule vs. Revlimid® capsule in healthy Chinese males. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29926217/),[ng] / [ml],383,264211,DB01041,Thalidomide
,29926217,AUC0-t,"In the fed state, the subjects had a Cmax of 389 ± 105 and 383 ± 101 ng/mL, respectively; an AUC0-t of 1770 ± 314 and 1740 ± 360 h ng/mL, respectively; and an AUC0-∞ of 1800 ± 316 and 1760 ± 362 h ng/mL, respectively.",Bioequivalence study of single-dose lenalidomide capsule vs. Revlimid® capsule in healthy Chinese males. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29926217/),[h·ng] / [ml],1770,264212,DB01041,Thalidomide
,29926217,AUC0-t,"In the fed state, the subjects had a Cmax of 389 ± 105 and 383 ± 101 ng/mL, respectively; an AUC0-t of 1770 ± 314 and 1740 ± 360 h ng/mL, respectively; and an AUC0-∞ of 1800 ± 316 and 1760 ± 362 h ng/mL, respectively.",Bioequivalence study of single-dose lenalidomide capsule vs. Revlimid® capsule in healthy Chinese males. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29926217/),[h·ng] / [ml],1740,264213,DB01041,Thalidomide
,29926217,AUC0-∞,"In the fed state, the subjects had a Cmax of 389 ± 105 and 383 ± 101 ng/mL, respectively; an AUC0-t of 1770 ± 314 and 1740 ± 360 h ng/mL, respectively; and an AUC0-∞ of 1800 ± 316 and 1760 ± 362 h ng/mL, respectively.",Bioequivalence study of single-dose lenalidomide capsule vs. Revlimid® capsule in healthy Chinese males. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29926217/),[h·ng] / [ml],1800,264214,DB01041,Thalidomide
,29926217,AUC0-∞,"In the fed state, the subjects had a Cmax of 389 ± 105 and 383 ± 101 ng/mL, respectively; an AUC0-t of 1770 ± 314 and 1740 ± 360 h ng/mL, respectively; and an AUC0-∞ of 1800 ± 316 and 1760 ± 362 h ng/mL, respectively.",Bioequivalence study of single-dose lenalidomide capsule vs. Revlimid® capsule in healthy Chinese males. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29926217/),[h·ng] / [ml],1760,264215,DB01041,Thalidomide
,31128208,α,The Cs values for α-TLD and β-TLD were not significantly different (α = 56.2 ± 0.5 μg·mL-1; β = 55.2 ± 0.2 μg·mL-1).,Systematic evaluation of the impact of solid-state polymorphism on the bioavailability of thalidomide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31128208/),[μg] / [ml],56.2,265169,DB01041,Thalidomide
,31128208,β,The Cs values for α-TLD and β-TLD were not significantly different (α = 56.2 ± 0.5 μg·mL-1; β = 55.2 ± 0.2 μg·mL-1).,Systematic evaluation of the impact of solid-state polymorphism on the bioavailability of thalidomide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31128208/),[μg] / [ml],55.2,265170,DB01041,Thalidomide
,31128208,maximum plasma concentration - Cmax,"The α-TLD provided a more favorable pharmacokinetic than the β-TLD (maximum plasma concentration - Cmax: 5.4 ± 0.90 μg·mL-1versus 2.6 ± 0.2 μg·mL-1; area under the curve of the concentration-time profile from time zero to infinity - AUC0-∞: 44.3 ± 8.8 μg·h·mL-1versus 33.9 ± 4.7 μg·h·mL-1; absolute bioavailability - F: 92.2 ± 18.5% versus 70.5 ± 9.9%, respectively).",Systematic evaluation of the impact of solid-state polymorphism on the bioavailability of thalidomide. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31128208/),[μg] / [ml],5.4,265171,DB01041,Thalidomide
,31128208,maximum plasma concentration - Cmax,"The α-TLD provided a more favorable pharmacokinetic than the β-TLD (maximum plasma concentration - Cmax: 5.4 ± 0.90 μg·mL-1versus 2.6 ± 0.2 μg·mL-1; area under the curve of the concentration-time profile from time zero to infinity - AUC0-∞: 44.3 ± 8.8 μg·h·mL-1versus 33.9 ± 4.7 μg·h·mL-1; absolute bioavailability - F: 92.2 ± 18.5% versus 70.5 ± 9.9%, respectively).",Systematic evaluation of the impact of solid-state polymorphism on the bioavailability of thalidomide. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31128208/),[μg] / [ml],2.6,265172,DB01041,Thalidomide
,31128208,area under the curve of the concentration-time profile from time zero to infinity - AUC0-∞,"The α-TLD provided a more favorable pharmacokinetic than the β-TLD (maximum plasma concentration - Cmax: 5.4 ± 0.90 μg·mL-1versus 2.6 ± 0.2 μg·mL-1; area under the curve of the concentration-time profile from time zero to infinity - AUC0-∞: 44.3 ± 8.8 μg·h·mL-1versus 33.9 ± 4.7 μg·h·mL-1; absolute bioavailability - F: 92.2 ± 18.5% versus 70.5 ± 9.9%, respectively).",Systematic evaluation of the impact of solid-state polymorphism on the bioavailability of thalidomide. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31128208/),[h·μg] / [ml],44.3,265173,DB01041,Thalidomide
,31128208,area under the curve of the concentration-time profile from time zero to infinity - AUC0-∞,"The α-TLD provided a more favorable pharmacokinetic than the β-TLD (maximum plasma concentration - Cmax: 5.4 ± 0.90 μg·mL-1versus 2.6 ± 0.2 μg·mL-1; area under the curve of the concentration-time profile from time zero to infinity - AUC0-∞: 44.3 ± 8.8 μg·h·mL-1versus 33.9 ± 4.7 μg·h·mL-1; absolute bioavailability - F: 92.2 ± 18.5% versus 70.5 ± 9.9%, respectively).",Systematic evaluation of the impact of solid-state polymorphism on the bioavailability of thalidomide. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31128208/),[h·μg] / [ml],33.9,265174,DB01041,Thalidomide
,31128208,absolute bioavailability - F,"The α-TLD provided a more favorable pharmacokinetic than the β-TLD (maximum plasma concentration - Cmax: 5.4 ± 0.90 μg·mL-1versus 2.6 ± 0.2 μg·mL-1; area under the curve of the concentration-time profile from time zero to infinity - AUC0-∞: 44.3 ± 8.8 μg·h·mL-1versus 33.9 ± 4.7 μg·h·mL-1; absolute bioavailability - F: 92.2 ± 18.5% versus 70.5 ± 9.9%, respectively).",Systematic evaluation of the impact of solid-state polymorphism on the bioavailability of thalidomide. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31128208/),%,92.2,265175,DB01041,Thalidomide
,31128208,absolute bioavailability - F,"The α-TLD provided a more favorable pharmacokinetic than the β-TLD (maximum plasma concentration - Cmax: 5.4 ± 0.90 μg·mL-1versus 2.6 ± 0.2 μg·mL-1; area under the curve of the concentration-time profile from time zero to infinity - AUC0-∞: 44.3 ± 8.8 μg·h·mL-1versus 33.9 ± 4.7 μg·h·mL-1; absolute bioavailability - F: 92.2 ± 18.5% versus 70.5 ± 9.9%, respectively).",Systematic evaluation of the impact of solid-state polymorphism on the bioavailability of thalidomide. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31128208/),%,70.5,265176,DB01041,Thalidomide
,15355928,Area under the concentration curve,"Area under the concentration curve values for mice, rabbits, and multiple myeloma patients were 4, 8, and 81 micromol/L. hour, respectively, and corresponding elimination half-lives were 0.5, 2.2, and 7.3 hours, respectively.","Thalidomide pharmacokinetics and metabolite formation in mice, rabbits, and multiple myeloma patients. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15355928/),[μM] / [h·l],4,265741,DB01041,Thalidomide
,15355928,Area under the concentration curve,"Area under the concentration curve values for mice, rabbits, and multiple myeloma patients were 4, 8, and 81 micromol/L. hour, respectively, and corresponding elimination half-lives were 0.5, 2.2, and 7.3 hours, respectively.","Thalidomide pharmacokinetics and metabolite formation in mice, rabbits, and multiple myeloma patients. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15355928/),[μM] / [h·l],8,265742,DB01041,Thalidomide
,15355928,Area under the concentration curve,"Area under the concentration curve values for mice, rabbits, and multiple myeloma patients were 4, 8, and 81 micromol/L. hour, respectively, and corresponding elimination half-lives were 0.5, 2.2, and 7.3 hours, respectively.","Thalidomide pharmacokinetics and metabolite formation in mice, rabbits, and multiple myeloma patients. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15355928/),[μM] / [h·l],81,265743,DB01041,Thalidomide
,15355928,elimination half-lives,"Area under the concentration curve values for mice, rabbits, and multiple myeloma patients were 4, 8, and 81 micromol/L. hour, respectively, and corresponding elimination half-lives were 0.5, 2.2, and 7.3 hours, respectively.","Thalidomide pharmacokinetics and metabolite formation in mice, rabbits, and multiple myeloma patients. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15355928/),h,0.5,265744,DB01041,Thalidomide
,15355928,elimination half-lives,"Area under the concentration curve values for mice, rabbits, and multiple myeloma patients were 4, 8, and 81 micromol/L. hour, respectively, and corresponding elimination half-lives were 0.5, 2.2, and 7.3 hours, respectively.","Thalidomide pharmacokinetics and metabolite formation in mice, rabbits, and multiple myeloma patients. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15355928/),h,2.2,265745,DB01041,Thalidomide
,15355928,elimination half-lives,"Area under the concentration curve values for mice, rabbits, and multiple myeloma patients were 4, 8, and 81 micromol/L. hour, respectively, and corresponding elimination half-lives were 0.5, 2.2, and 7.3 hours, respectively.","Thalidomide pharmacokinetics and metabolite formation in mice, rabbits, and multiple myeloma patients. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15355928/),h,7.3,265746,DB01041,Thalidomide
,19671864,Overall response rate,"Overall response rate was 42%, including three partial responses among nine bortezomib refractory patients.",Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19671864/),%,42,267419,DB01041,Thalidomide
,21859393,C(max),"Mean C(max), AUC(0-∞) and t(max) values for apremilast in plasma were 333 ng/mL, 1970 ng*h/mL and 1.5 h.","Disposition, metabolism and mass balance of [(14)C]apremilast following oral administration. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21859393/),[ng] / [ml],333,267675,DB01041,Thalidomide
,21859393,AUC(0-∞),"Mean C(max), AUC(0-∞) and t(max) values for apremilast in plasma were 333 ng/mL, 1970 ng*h/mL and 1.5 h.","Disposition, metabolism and mass balance of [(14)C]apremilast following oral administration. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21859393/),[h·ng] / [ml],1970,267676,DB01041,Thalidomide
,21859393,t(max),"Mean C(max), AUC(0-∞) and t(max) values for apremilast in plasma were 333 ng/mL, 1970 ng*h/mL and 1.5 h.","Disposition, metabolism and mass balance of [(14)C]apremilast following oral administration. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21859393/),h,1.5,267677,DB01041,Thalidomide
,30862646,Overall response rate,Overall response rate was 62%; median duration of response was 18.7 months; median progression-free survival was 17.6 months.,A phase 1b study of isatuximab plus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30862646/),%,62,268793,DB01041,Thalidomide
,30862646,duration of response,Overall response rate was 62%; median duration of response was 18.7 months; median progression-free survival was 17.6 months.,A phase 1b study of isatuximab plus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30862646/),,18,268794,DB01041,Thalidomide
,30862646,progression-free survival,Overall response rate was 62%; median duration of response was 18.7 months; median progression-free survival was 17.6 months.,A phase 1b study of isatuximab plus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30862646/),month,17.6,268795,DB01041,Thalidomide
,9871424,area under the plasma concentration-time curve (AUC0-infinity),"The mean +/- SD area under the plasma concentration-time curve (AUC0-infinity) for ethinyl estradiol was 6580 +/- 1100 ng.h/L at baseline and 5970 +/- 1560 ng.h/L after the thalidomide regimen (paired t test, P > .05).",Thalidomide does not alter the pharmacokinetics of ethinyl estradiol and norethindrone. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9871424/),[h·ng] / [l],6580,269060,DB01041,Thalidomide
,9871424,area under the plasma concentration-time curve (AUC0-infinity),"The mean +/- SD area under the plasma concentration-time curve (AUC0-infinity) for ethinyl estradiol was 6580 +/- 1100 ng.h/L at baseline and 5970 +/- 1560 ng.h/L after the thalidomide regimen (paired t test, P > .05).",Thalidomide does not alter the pharmacokinetics of ethinyl estradiol and norethindrone. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9871424/),[h·ng] / [l],5970,269061,DB01041,Thalidomide
,9871424,AUC0-infinity,"No accumulation of thalidomide was seen after 21 days of therapy: day 1 AUC0-infinity 41.1 +/- 13.9 micrograms.h/mL; day 21 AUC0-infinity 59.6 +/- 27.3 micrograms.h/mL (paired t test, P > .05).",Thalidomide does not alter the pharmacokinetics of ethinyl estradiol and norethindrone. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9871424/),[h·μg] / [ml],41.1,269062,DB01041,Thalidomide
,9871424,AUC0-infinity,"No accumulation of thalidomide was seen after 21 days of therapy: day 1 AUC0-infinity 41.1 +/- 13.9 micrograms.h/mL; day 21 AUC0-infinity 59.6 +/- 27.3 micrograms.h/mL (paired t test, P > .05).",Thalidomide does not alter the pharmacokinetics of ethinyl estradiol and norethindrone. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9871424/),[h·μg] / [ml],59.6,269063,DB01041,Thalidomide
,28092421,overall response rate,The overall response rate was 88.5%.,"Carfilzomib, lenalidomide and dexamethasone in patients with heavily pretreated multiple myeloma: A phase 1 study in Japan. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28092421/),%,88.5,271881,DB01041,Thalidomide
,29529709,flow rate,"The analytes were extracted from plasma (100 μL) by liquid-liquid extraction with ethyl acetate and then separated on a BETASIL C18 column (4.6 × 150 mm, 5 μm) with mobile phase composed of methanol-water containing 0.1% formic acid (70:30, v/v) in isocratic mode at a flow rate of 0.5 mL/min.",A validated LC-MS/MS method for the simultaneous determination of thalidomide and its two metabolites in human plasma: Application to a pharmacokinetic assay. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29529709/),[ml] / [min],0.5,272267,DB01041,Thalidomide
,29529709,m/z,"The precursor-to-product ion transitions m/z 259.1 → 186.1 for thalidomide, m/z 273.2 → 161.3 for 5-hydroxy thalidomide, m/z 273.2 → 146.1 for 5'-hydroxy thalidomide and m/z 163.1 → 107.1 for umbelliferone (internal standard, IS) were used for quantification.",A validated LC-MS/MS method for the simultaneous determination of thalidomide and its two metabolites in human plasma: Application to a pharmacokinetic assay. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29529709/),,273.2,272268,DB01041,Thalidomide
,29529709,m/z,"The precursor-to-product ion transitions m/z 259.1 → 186.1 for thalidomide, m/z 273.2 → 161.3 for 5-hydroxy thalidomide, m/z 273.2 → 146.1 for 5'-hydroxy thalidomide and m/z 163.1 → 107.1 for umbelliferone (internal standard, IS) were used for quantification.",A validated LC-MS/MS method for the simultaneous determination of thalidomide and its two metabolites in human plasma: Application to a pharmacokinetic assay. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29529709/),,146.1,272269,DB01041,Thalidomide
,29529709,m/z,"The precursor-to-product ion transitions m/z 259.1 → 186.1 for thalidomide, m/z 273.2 → 161.3 for 5-hydroxy thalidomide, m/z 273.2 → 146.1 for 5'-hydroxy thalidomide and m/z 163.1 → 107.1 for umbelliferone (internal standard, IS) were used for quantification.",A validated LC-MS/MS method for the simultaneous determination of thalidomide and its two metabolites in human plasma: Application to a pharmacokinetic assay. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29529709/),,163.1,272270,DB01041,Thalidomide
,29529709,m/z,"The precursor-to-product ion transitions m/z 259.1 → 186.1 for thalidomide, m/z 273.2 → 161.3 for 5-hydroxy thalidomide, m/z 273.2 → 146.1 for 5'-hydroxy thalidomide and m/z 163.1 → 107.1 for umbelliferone (internal standard, IS) were used for quantification.",A validated LC-MS/MS method for the simultaneous determination of thalidomide and its two metabolites in human plasma: Application to a pharmacokinetic assay. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29529709/),,107.1,272271,DB01041,Thalidomide
